Introduction {#s1}
============

In order to adapt to changing animal physiology or tissue damage, tissue stem cells must respond to long-range signals emitted from other organs ([@bib45]). For instance, stem cells in the intestine, central nervous system, hematopoietic system, and germline are regulated by insulin and nutritional status ([@bib10]; [@bib11]; [@bib35]; [@bib36]; [@bib41]; [@bib50]; [@bib66]; [@bib81]), and the circadian rhythm affects skin and hematopoietic stem cells ([@bib30]; [@bib43]). Age-related changes in blood-borne factors regulate muscle and neural stem cell aging ([@bib6]; [@bib13]; [@bib32]; [@bib65]; [@bib76]). However, few long-range signals, such as prostaglandin E2 ([@bib48]) or those that are modulated by prolonged fasting ([@bib11]), have been found to augment the ability of tissue stem cells to repair damaged tissues. Understanding how long-range signals regulate tissue stem cell function may pave the way to harness stem cells for regenerative medicine.

The hematopoietic system has a remarkable regenerative potential demonstrated by the ability of a single hematopoietic stem cell (HSC) to rebuild the entire hematopoietic system upon transplantation, and to regenerate the tissue upon damage, such as those caused by chemo- or radio-therapies. A network of factors operating cell intrinsically or extrinsically promote regeneration by HSCs ([@bib42]). Cell-extrinsic factors produced by the HSC niche, such as the stem cell factor ([@bib83]), angiogenin ([@bib21]), pleiotrophin ([@bib28]), EGF ([@bib16]), or Dkk1 ([@bib27]) have particular therapeutic potential as they may be used as radioprotectors or radiomitigators to accelerate the recovery of the hematopoietic system ([@bib12]). Despite the extensive interest in augmenting the regenerative potential of HSCs, much remains to be investigated regarding the factors that promote hematopoietic regeneration by HSCs, and the mode of action of these factors.

The female sex hormone estrogen is an emerging soluble factor involved in specification and self-renewal of HSCs. Estradiol (E2), the most potent endogenous estrogen, is predominantly produced by the granulosa cells of the ovaries and regulates a diverse array of tissues, such as the reproductive organs, bone, breast, brain, and the hematopoietic system ([@bib18]). During zebrafish development, maternal E2 stored in the yolk promotes the specification of HSCs ([@bib9]). In mice, E2 produced by the ovaries stimulates division of HSCs via the estrogen receptor α (ERα). Exogenous E2, when administered at a physiological level similar to the level observed during pregnancy, also promotes division of HSCs in male mice, indicating that the E2-ERα pathway activation is sufficient induce HSC division ([@bib46]). A selective estrogen receptor modulator tamoxifen also promoted HSC division similar to E2 ([@bib57]). Interestingly, even though E2 significantly increases HSC divisions, unlike infection or interferon responses it does not lead to HSC depletion ([@bib1]; [@bib19]; [@bib20]; [@bib52]; [@bib56]). This raises a question of whether HSC function is impaired by E2 at the cost of increased division, or whether E2 elicits a protective mechanism to maintain HSCs while stimulating HSC division.

The unfolded protein response (UPR) is an evolutionally conserved mechanism that promotes protein homeostasis (proteostasis) upon various stresses by increasing the expression of protein foldases and chaperones ([@bib26]; [@bib31]; [@bib77]). Three pathways --- the PERK-eIF2α-CHOP pathway, the ATF6 pathway, and the IRE1-XBP1 pathway --- coordinately regulate the UPR in mammals. Gpr78 (also called BiP), a chaperone localized in the endoplasmic reticulum (ER), tethers the three ER stress sensors (PERK, ATF6, and IRE1) in inactive states during homeostasis. Upon ER stress, Gpr78 disassociates with PERK, ATF6, and IRE1 to allow them to become activated and induce the UPR. The UPR plays essential roles in highly secretary cells, such as plasma cells and pancreatic β-cells that have high protein flux through the ER. In addition, recent evidence established that the UPR is also involved in a wide range of pathological states, since many stress signals impinge upon the ER ([@bib39]). Interestingly, evidence in *C.elegans* indicates that the UPR can be extrinsically activated, potentially mediated by an as yet unidentified neurotransmitter ([@bib69]; [@bib70]; [@bib71]). Whether the UPR in mammalian tissue stem cells is regulated by systemic factors remains elusive.

Here we demonstrate that the female sex hormone E2 increases the regenerative capacity of HSCs upon transplantation, and improves bone marrow and peripheral blood recovery after irradiation. ERα, in response to E2 stimulation, activated a protective UPR by inducing the expression of Ire1α in HSCs. The Ire1α-Xbp1 branch of the UPR augmented proteotoxic stress resistance in HSCs and promoted regeneration. Our results reveal that the UPR in HSCs can be modulated by systemic factors, extending the systemic activation of the UPR to tissue stem cell biology.

Results {#s2}
=======

Estradiol promotes the regenerative capacity of HSCs {#s2-1}
----------------------------------------------------

To address the question of whether E2 stimulation affects HSC function, we first performed colony-forming assays by sorting single HSCs ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, for gating strategy) from oil- or E2-treated male mice into methylcellulose media. We used male mice unless otherwise noted since estrogen levels fluctuate in females during the estrus cycle. HSCs from E2-treated animals exhibited a greater proportion of immature colonies containing granulocytes, erythrocytes, macrophages, and megakaryocytes (gemM) compared to HSCs from oil-treated mice ([Figure 1A](#fig1){ref-type="fig"}), suggesting that E2 increases the multipotency of HSCs. To quantify the effects of E2 in promoting megakaryocytic potential of HSCs we used a collagen-based media that enables outgrowth and enumeration of megakaryocytes. Although freshly isolated HSCs were incapable of forming any colonies in this media, potentially due to the lack of HSC supportive cytokines, HSCs after a brief culture in media containing cytokines exhibited robust megakaryocytic differentiation in this system. We found that HSCs isolated from E2-treated mice not only formed more colonies but they also exhibited a significantly increased capacity to form colonies containing megakaryocytes ([Figure 1B](#fig1){ref-type="fig"}). Consistent with the increased megakaryopoiesis by E2, we observed significantly more megakaryocytes in the bone marrow of E2-treated mice than oil-treated mice ([Figure 1C--D](#fig1){ref-type="fig"}). These results indicate that E2 treatment enhances the clonogenic potential of HSCs towards myeloid, erythroid, and megakaryocytic lineages.

![Estrogen Enhances the Myeloid Potential of HSCs.\
(**A**) Colony formation by single HSCs from control or E2 treated *Esr1^fl/fl^* (WT) and *Mx1-Cre; Esr1^fl/fl^* (Esr1^Δ/Δ^) mice (96 wells per animal, n = 4 assays/group). Colonies were collected, cytospun, and scored after Wright Giemsa staining. gemM: granulocyte, erythroid, monocyte, megakaryocyte; gmM: granulocyte monocyte megakaryocyte; gme: granulocyte, monocyte, erythroid; gm: granulocyte, monocyte; M: megakaryocyte; m: monocyte; e: erythroid. Red and green lines indicate significant interaction of treatment and genotype of gemM and gm, respectively (\*\*\*p\<0.001, ANOVA) (**B**) Megakaryocyte differentiation potential in collagen-based MegaCult assays (n = 6, three independent experiments, two technical replicates per experiment). Meg, colonies containing exclusively megakaryocytes as indicated by cholinesterase staining; Mixed, colonies containing both megakaryocytes and other myeloid cells; Non, colony with no megakaryocytes. \*p\<0.05, ANOVA. (**C**) Numbers of CD41^+^ megakaryocytes as indicated by immunofluorescent staining of bone marrow sections (n = 10, 5 fields of view per section). (**D**) Representative images of CD41 stained bone marrow sections from oil- and E2-treated mice. Scale bar represents 50 μm. (**E--J**) Levels of donor (GFP^+^) engraftment in recipient mice that were transplanted with 100 GFP^+^ HSCs (oil- or E2-treated *Ubc-GFP; Esr1^fl/fl^* (n = 4 donors each, 24 and 26 recipients respectively) or *Ubc-GFP; Mx1-Cre; Esr1^fl/fl^ (*n = 3 donors each, 14 and 23 recipients respectively) and 2 × 10^5^ competitor GFP^-^ cells. Each panel represents donor chimerisms in (**E**) overall mononuclear cells, (**F**) Mac-1/Gr-1^+^ myeloid cells, (**G**) CD41^+^ FSC/SSC^low^ platelets, (**H**) Ter119^+^ FSC/SSC^low^ red blood cells, (**I**) B220^+^ B-cells, and (**J**) CD3^+^ T-cells. All data represent mean ±standard deviation; \*p\<0.05; \*\*p\<0.01; and \*\*\*p\<0.001 by Student's t-test unless otherwise noted.](elife-31159-fig1){#fig1}

We then tested whether E2 treatment affects multilineage reconstitution of HSCs. To this end, we competitively transplanted 100 purified HSCs isolated from male *Ubc-GFP* mice that were treated with either oil or E2 for one week. Compared to oil-treated controls, HSCs isolated from E2-treated mice exhibited enhanced reconstitution of Mac-1/Gr-1^+^ myeloid cells, Ter119^+^ red blood cells, and CD41^+^ platelets ([Figure 1E--H](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B--C](#fig1s1){ref-type="fig"}). Interestingly, HSCs from E2-treated mice did not exhibit reduced lymphoid cell reconstitution ([Figure 1I--J](#fig1){ref-type="fig"}), indicating that the enhanced myeloid/erythroid/megakaryocytic cell reconstitution by E2 stimulated HSCs was not at the cost of lymphoid cell reconstitution. Next, we ascertained if E2 affects long-term self-renewal capacity by performing secondary transplantation. Reconstituted bone marrow derived from E2-treated HSCs gave rise to stable engraftment across all lineages in secondary recipients ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Therefore, although E2 treatment increases HSC division ([@bib46]), it does not negatively affect long-term self-renewal capacity of HSCs but rather increases HSC function.

To determine whether ERα expressed in hematopoietic cells is responsible for the effects of E2 on HSC function, we treated *Mx1-Cre; Esr1^fl/fl^* mice (and control littermates) with poly I:C to delete ERα from the hematopoietic system (hereafter described as ERα-deficient mice). ERα-deficient mice and control littermates were then treated with E2 for one week followed by colony assays to examine HSC function. The increased ability of E2-stimulated HSCs to form immature colonies ([Figure 1A](#fig1){ref-type="fig"}) and megakaryocytes ([Figure 1B](#fig1){ref-type="fig"}) was abolished by deleting ERα, indicating that ERα promotes HSC function upon E2 stimulation.

Further, we determined whether the increased capacity of HSCs to reconstitute the hematopoietic system upon transplantation was dependent on ERα. 100 HSCs isolated from ERα-deficient and control littermates treated with either oil or E2 were transplanted along with competitor cells. ERα-deficient HSCs without E2 stimulation exhibited intact long-term multilineage reconstitution ([Figure 1E--J](#fig1){ref-type="fig"}), indicating that ERα is dispensable for steady state HSC function, as shown previously ([@bib73]). However, ERα-deficient HSCs did not exhibit increased myeloid/erythroid/megakaryocytic cell reconstitution upon E2 treatment as observed in wild-type HSCs ([Figure 1F--H](#fig1){ref-type="fig"}). These results establish that the E2-ERα pathway enhances functions within the hematopoietic cells to promote myeloid/erythroid/megakaryocytic reconstitution by HSCs in response to E2.

Estradiol promotes hematopoietic recovery after irradiation {#s2-2}
-----------------------------------------------------------

The results presented above demonstrate that E2 promotes hematopoietic regeneration by HSCs in a transplantation model. As another model of hematopoietic regeneration, we examined the effects of E2 on hematopoiesis after injury imposed by total body irradiation (TBI) ([@bib16]; [@bib21]; [@bib27]; [@bib28]). We treated male mice with oil or E2 for one week, and irradiated them with a sublethal dose of 600 cGy ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} for experimental scheme). Serial sampling of peripheral blood after irradiation revealed that E2 treatment prior to irradiation significantly accelerated the rate at which platelets and white blood cells recover, whereas the effects on red blood cell counts were modest ([Figure 2A--C](#fig2){ref-type="fig"}). To determine whether ERα is responsible for the effects of E2 on hematopoietic regeneration after irradiation, we administered poly I:C-treated *Mx1-Cre; Esr1^fl/fl^* mice with E2 followed by sublethal irradiation. The accelerated recovery of RBC, PLT, and WBC in E2-treated mice was not observed in ERα-deficient mice, indicating that ERα is required for E2 to promote regeneration ([Figure 2D--F](#fig2){ref-type="fig"}). These results indicate that E2 treatment promotes hematopoietic recovery after stress, consistent with our prior finding that E2 promotes the reconstitution potential of HSCs.

![Estrogen Promotes Hematopoietic Recovery After Irradiation.\
(**A--C**) Mean PB counts of (**A**) platelets, (**B**) white blood cells, and (**C**) red blood cells of oil- and E2-treated mice (black and red lines, respectively. n = 4 Oil, n = 5 E2, two independent experiments). \*p\<0.05 by Student's t-test. (**D--F**) Mean PB counts of (**D**) platelets, (**E**) white blood cells, and (**F**) red blood cells of control or *ERα*-deficient mice, treated with either oil or E2. Data were collected 14 days after TBI. \*\*\*p\<0.001, ANOVA. (**G**) Survival curves of C57BL/6 male mice treated with oil or E2 for 1 week followed by 800cGy TBI. \*\*p\<0.01 by a log-rank test. (**H**) Survival curves of C57BL/6 male and female mice following 800cGy TBI. \*p\<0.05 by a log-rank test. All data represent mean ±standard deviation.](elife-31159-fig2){#fig2}

The positive effects of E2 on hematopoietic recovery improved the survival of mice after irradiation. Male mice were treated with oil or E2 for one week, and irradiated with a semi-lethal dose of 800 cGy. Whereas 89% of oil-treated mice died within 28 days after irradiation, E2 treatment significantly reduced the fraction (to 29%) of mice succumbing to irradiation-induced lethality ([Figure 2G](#fig2){ref-type="fig"}). This increased survival is consistent with an early study that described that female mice are more radioresistant than male mice, which we confirmed here ([Figure 2H](#fig2){ref-type="fig"}), and that the estrus cycle affects the radiosensitivity of female mice ([@bib54]). These results suggest that the positive effect of E2 on hematopoietic regeneration improves the survival of mice after hematopoietic injury.

Estradiol accelerates hematopoietic progenitor cell regeneration after ionizing radiation {#s2-3}
-----------------------------------------------------------------------------------------

Our observation that E2 treatment accelerated the recovery of peripheral blood cells prompted us to examine whether E2 improves hematopoietic stem/progenitor cell (HSPC) function after irradiation. E2 treatment significantly accelerated the recovery of whole bone marrow (WBM) cells at days 5, 7, and 14 after irradiation ([Figure 3A](#fig3){ref-type="fig"}), consistent with the accelerated recovery of blood cells. We then examined whether E2 affects HSPC frequency after irradiation. Irradiation caused rapid and prolonged depletion of immature lineage^-^Sca-1^+^c-kit^+^ (LSK) cells for up to two weeks post irradiation (0.17 ± 0.04% before irradiation versus 0.02 ± 0.02% at two weeks after irradiation). Intriguingly, E2 treatment prior to irradiation significantly increased the frequency of LSK cells compared to control oil-treated mice 14 days after TBI ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Combined with the increased numbers of WBM cells in E2-treated irradiated mice, E2 treatment induced a 6.3-fold expansion (p\<0.01) of the size of LSK pool at day 14 ([Figure 3C](#fig3){ref-type="fig"}), suggesting that E2 treatment prior to TBI promotes LSK regeneration. E2 treatments every other day post-TBI also increased hematopoietic cell numbers after irradiation ([Figure 3---figure supplement 1B--E](#fig3s1){ref-type="fig"}). In contrast, E2 treatment did not significantly affect the frequency of lineage^-^Sca-1^-^c-kit^+^ committed myeloid progenitors (MP), but did increase the total numbers of these cells ([Figure 3---figure supplement 1F--H](#fig3s1){ref-type="fig"}). We assessed apoptosis rates in lineage^-^ BM cells shortly after irradiation exposure by Annexin V staining and observed significantly lower numbers of Annexin V^+^ cells in E2 treated cohorts at both days 3 and 5 post-TBI ([Figure 3---figure supplement 1I](#fig3s1){ref-type="fig"}). These results suggest that the preservation of HSPC numbers by E2 treatment could be a function of enhanced proliferation ([@bib46]), protection from irradiation-induced apoptosis, or a combination of both. Collectively, these results suggest that E2 not only enhances recuperation of peripheral blood cells after irradiation ([Figure 2A--C](#fig2){ref-type="fig"}), but also enhances hematopoietic regeneration by promoting the recovery of immature HSPCs.

![Estrogen Promotes HSPC Regeneration After Irradiation.\
(**A**) Bone marrow cellularity (**A**), LSK frequencies (**B**), and total numbers of LSK cells (**C**) were analyzed at 3, 5, 7, and 14 days after 600cGy of TBI. E2 treatment significantly accelerated the recovery of bone marrow cellularity, and the frequencies and the total numbers of LSK cells. (**B--C**) Frequencies (**B**) and total numbers (**C**) of LSK cells in the bone marrow drop significantly 14 days after 600cGy of irradiation; this affect is rescued by E2 treatment in wild-type mice but not in *ERα*-deficient mice (n = 7 over four independent experiments). (**D**) Competitive transplantation assays using 5 × 10^5^ WBM cells from Ubc-GFP^+^ unirradiated mice (green lines) or sublethally irradiated, oil-treated mice (black lines) or sublethally irradiated E2-treated mice (red lines) along with competitor cells (n = 8, two donors, four recipients per donor). E2 pretreatment significantly rescued the ability of WBM cells to reconstitute the myeloid cells, platelets, and red blood cells after irradiation. (**E--G**) Bone marrow cellularity (**E**), LSK frequencies (**F**), and total numbers of LSK cells (**G**) in the bone marrow are significantly lower 14 days after 600cGy of irradiation (IR) compared to unirradiated mice (Un). This effect is rescued by E2 treatment in wild-type mice but not in *ERα*-deficient mice (n = 7, four independent experiments). All data represent mean ±standard deviation; \*p\<0.05; \*\*p\<0.01; and \*\*\*p\<0.001 by Student's t-test in (**A--D**), and by ANOVA in (**E--G**).](elife-31159-fig3){#fig3}

Next, we examined whether E2 affects HSCs regeneration after irradiation. Since irradiation compromised the expression of several HSC markers (data not shown and ([@bib63]), we accessed long-term reconstitution capacity as a surrogate of HSC function by transplanting WBM cells from irradiated animals that had been treated with control oil or E2 into wild-type recipients. Cells from irradiated, oil-treated mice exhibited negligible reconstitution upon transplantation ([Figure 3D](#fig3){ref-type="fig"}). Strikingly, we observed that cells from mice that were treated with E2 prior to irradiation demonstrated a preservation of long-term reconstitution potential in the myeloid, erythroid, and platelet lineages --- a feature that reflects HSC activity ([@bib51]; [@bib53]; [@bib55]; [@bib80]) --- although their lymphoid-reconstitution potential was impaired. These results demonstrate that E2 treatment improves the regeneration of the hematopoietic system, augmenting the function of cells with long-term myeloid reconstitution capacity.

We then tested whether ERα regulates HSPC regeneration after irradiation. Control and ERα-deficient mice were treated with oil or E2, sublethally irradiated, and analyzed by flow cytometry. We found that deleting ERα abolished the accelerated recovery of bone marrow cellularity after irradiation in response to prior E2 treatment ([Figure 3E](#fig3){ref-type="fig"}). Furthermore, whereas E2 treatment promoted the regeneration of LSK cells in the bone marrow after irradiation, it failed to do so in ERα-deficient mice ([Figure 3F,G](#fig3){ref-type="fig"}). These results indicate that ERα, which is highly expressed in HSPCs, promotes hematopoietic regeneration in response to E2 stimulation.

Estradiol activates the unfolded protein response (UPR) pathway in HSCs {#s2-4}
-----------------------------------------------------------------------

To understand the mechanism through which E2 increases HSC function, we employed RNA-seq to profile the gene expression changes of HSCs upon E2 treatment. Control and *ERα*-deficient male mice were treated with oil or E2 for one week, and HSCs were isolated for RNA-seq. Unsupervised hierarchical clustering analysis revealed that wild-type HSCs from E2-treated mice clustered separately from other groups, indicating that E2 induces a transcriptional response that is dependent on ERα ([Figure 4A](#fig4){ref-type="fig"}). We then performed gene set enrichment analysis (GSEA) to identify gene signatures enriched in HSCs following E2 treatment. The GSEA revealed that Myc and E2F target genes and genes involved in cell cycle regulation were enriched in E2-treated HSCs ([Figure 4B](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A--H](#fig4s1){ref-type="fig"}), consistent with our finding that E2-treated HSCs are more proliferative ([@bib46]). Several Myc target genes were induced by E2 treatment in vitro ([Figure 4---figure supplement 1B--H](#fig4s1){ref-type="fig"}), although c-Myc, N-Myc, and L-Myc were not induced in HSCs by E2 as determined by RNA-seq (data not shown). Additionally, several megakaryocyte lineage genes were increased in E2 treated HSCs ([Figure 4---figure supplement 1I](#fig4s1){ref-type="fig"}). Interestingly, we found that a gene set representing the unfolded protein response (UPR) was also upregulated in HSCs in response to E2 ([Figure 4B](#fig4){ref-type="fig"} [Figure 4---figure supplement 1J](#fig4s1){ref-type="fig"}). We focused specifically on the UPR gene set and examined whether the enrichment of the UPR gene set upon E2 treatment depends upon ERα. To this end, we performed GSEA in a pairwise fashion comparing the four HSC datasets with each other. We found that wild-type HSCs from E2-treated mice have significant (p\<0.005) enrichment of UPR related genes compared to all other treatment groups, including E2-treated ERα-deficient HSCs ([Figure 4C](#fig4){ref-type="fig"}). This analysis indicates that E2 treatment induces the UPR in HSCs in an ERα-dependent manner. Importantly, we found that the expression of *Ern1*, which encodes a key regulator of the UPR, Ire1α, was significantly increased in E2-treated HSCs ([Figure 4A and D](#fig4){ref-type="fig"}). The increased expression of *Ern1* was also evident in our previously published microarray analysis (GDS4944) ([@bib46]). Moreover, multiple chaperones were induced in HSCs by E2 ([Figure 4---figure supplement 1K](#fig4s1){ref-type="fig"}). These results suggested that the UPR was increased in HSCs after E2 exposure.

![Estrogen Activates the Ire1α-Xbp1 Branch of the UPR.\
(**A**) Unsupervised hierarchical clustering of genes with log2 fold change larger than one identified by RNA-seq. Top 25 genes for each cluster are shown. \# indicates *Ern1*, which encodes Ire1α. (**B**) GSEA was performed between oil- and E2-treated HSCs. Gene sets significantly enriched in E2-treated HSCs are shown. (**C**) Pair wise GSEA was performed to test the enrichment of UPR-related genes in wild-type or *ERα*-deficient HSCs after either oil- or E2-treatment (left). E2-treated wild-type HSCs had enrichment of UPR genes, as indicated by the cumulative enrichment score (right). (**D**) Fragments per kilobase of exon per million fragments mapped (FPKM) of *Ern1* transcript was increased in HSCs upon E2 treatment, and this increase was dependent on ERα. \*\*p\<0.01 by two-way ANOVA. (**E**) Quantitative PCR assays confirmed that the induction of *Ire1α* in HSCs, as well as in MPPs, upon E2 treatment was dependent on ERα (n = 3, two independent experiments). \*p\<0.05 by two-way ANOVA. (**F**) *Xbp1* splicing was determined by a two-color Taqman assay. *Xbp1* splicing was induced in HSCs and MPPs upon E2 treatment in an ERα-dependent manner. The ratio between spliced (Xbp1s) to unspliced (Xbp1u) Xbp1 transcript is shown (n = 4, two independent experiments). \*p\<0.05 by two-way ANOVA. (**G**) *Xbp1* splicing was also determined by flow cytometry using the ERAI strain. Grey histogram represents the background signal from ERAI^-^ HSCs. \*\*p\<0.01; and \*\*\*p\<0.001 by Student's t-test. (**H**) Immunoblotting was performed using HSC/MPP (CD48^-/low^LSK), progenitor cells (CD48^+^LSK), and WBM cells. Both Ire1α and Xbp1s protein levels were increased by E2 treatment in immature cells. All data represent mean ±standard deviation.](elife-31159-fig4){#fig4}

Three branches, governed by the PERK-eIF2α-CHOP, ATF6, and IRE1-XBP1 pathways, regulate the UPR. Each of these pathways controls the expression of multiple UPR target genes, consisting of chaperones and genes involved in metabolism ([@bib26]). To better understand how E2 activates UPR in HSCs, we performed qRT-PCR on key mediators of the UPR pathway. Consistent with our RNA-seq analysis, we confirmed that the induction of *Ern1* in HSCs upon E2 treatment was fully dependent on ERα ([Figure 4E](#fig4){ref-type="fig"}). However, the components of the two other UPR branches, such as *Ddit3* (encoding CHOP), *Eifak3* (encoding PERK), and, *Atf6*, were unaffected by E2 treatment ([Figure 4---figure supplement 2C](#fig4s2){ref-type="fig"}), suggesting that the Ire1α pathway is activated upon E2 stimulation. To test whether Ire1α was activated in a lineage-biased subset of HSCs we examined Ire1α expression in CD48^-/low^ LSK cells fractionated based on CD150 expression levels ([Figure 4---figure supplement 2A,B](#fig4s2){ref-type="fig"}) ([@bib2]). Ire1α levels were increased consistently across each subset indicating that E2 acts on the entirety of the HSC pool.

Ire1α is a bifunctional protein with a serine-threonine kinase domain and an RNase domain. In response to ER stress, the RNase activity of Ire1α becomes activated and splices *Xbp1* mRNA ([@bib15]; [@bib82]). This *Xbp1* splicing event produces a functional Xbp1s protein that serves as a transcriptional regulator critical for the induction of UPR response genes ([@bib26]; [@bib31]). We thus tested whether *Xbp1* splicing is induced upon E2 treatment in HSCs using a quantitative PCR method that detects both the unspliced and spliced forms of *Xbp1*. We found that *Xbp1* splicing was induced in response to E2 treatment in both HSCs and MPPs, but not in WBM cells, suggesting that immature hematopoietic progenitor cells are more sensitive to E2 treatment to activate Xbp1 ([Figure 4F](#fig4){ref-type="fig"}). This was confirmed using the *ERAI* strain, in which *Xbp1* splicing can be monitored by Venus fluorescence ([@bib29]). Flow cytometry analysis of cells isolated from *ERAI* mice treated with oil or E2 revealed that *Xbp1* splicing, as determined by Venus fluorescence, was significantly increased by E2 treatment in HSCs and MPPs, but not in lineage^-^ and WBM cells ([Figure 4G](#fig4){ref-type="fig"}). Importantly, *Xbp1* splicing was entirely dependent upon *ERα*, consistent with our finding that the E2-ERα pathway induces *Ire1α* expression ([Figure 4F](#fig4){ref-type="fig"}). We also confirmed that the protein levels of Ire1α and Xbp1s were increased upon E2 treatment in both CD48^-/low^ (containing HSCs and MPPs) and CD48^+^ fractions of the LSK population, but not in WBM cells ([Figure 4H](#fig4){ref-type="fig"}). Taken together, these results indicate that the Ire1α-Xbp1 branch of the UPR is activated in E2-treated HSCs. As increased protein synthesis is associated with proliferation and may activate the UPR, we tested whether E2-induced activation of the Ire1α-Xbp1 pathway is a general feature of activated HSCs. Using a protocol adapted from previous reports ([@bib37]; [@bib59]; [@bib60]), we tested whether E2 treatment affected protein translation rates in HSCs. Consistent with a previous report ([@bib60]), HSCs and MPPs had significantly lower protein translation compared to whole bone marrow cells ([Figure 4---figure supplement 2D](#fig4s2){ref-type="fig"}). However, the protein synthesis rate of HSCs did not significantly change upon E2 treatment ([Figure 4---figure supplement 2D](#fig4s2){ref-type="fig"}), consistent with a previous report demonstrating that cycling HSCs do not have increased protein translation ([@bib61]). Moreover, inducing HSCs to proliferate (either by G-CSF or poly I:C administration) did not increase *Ire1α* expression ([Figure 4---figure supplement 2E,F](#fig4s2){ref-type="fig"}), and these treatment had limited effects on the expression of chaperone genes ([Figure 4---figure supplement 2G](#fig4s2){ref-type="fig"}) compared to the broad effects E2 had on chaperones ([Figure 4---figure supplement 1K](#fig4s1){ref-type="fig"}). Thus, activation of the Ire1α-Xbp1 pathway is not a general response used by HSCs upon cell cycle activation.

Ire1α is a direct target of ERα in HSPCs {#s2-5}
----------------------------------------

Genome wide ERα binding profiles have been extensively studied in other cell types, but ERα binding sites in hematopoietic cells remain elusive. Moreover, profiling the genome wide ERα binding sites in rare HSCs is technically challenging. To begin to understand the changes in transcriptional factor landscapes induced by E2 treatment in purified HSCs, we profiled the chromatin accessibility sites in oil- or E2-treated HSCs using ATAC-seq ([@bib8]). We reasoned that if ERα is indeed a major regulator of E2-induced transcriptional changes, we would observe changes in chromatin accessibility in response to E2 with ERα footprints, which could be discovered by the presence of estrogen response elements (ERE). 5,000 HSCs were isolated from oil- or E2-treated mice, and the isolated nuclei were subject to an ATAC-seq protocol. We observed highly concordant ATAC-seq profiles across samples, identifying 51,230 overlapping peaks between all replicates ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). We identified a subset of peaks that were differentially upregulated in E2-treated cells ([Figure 5A](#fig5){ref-type="fig"}). Both the de novo and the supervised motif search identified ERE as the most enriched motif found in differentially regulated peaks, consistent with the idea that ERα is the major regulator of the transcriptional changes induced by E2 in HSCs ([Figure 5B](#fig5){ref-type="fig"}). Of interest, one of the differential peaks present in E2-treated HSCs was located approximately 2.5 kb upstream of the TSS of *Ire1α* (termed peak 2) ([Figure 5C](#fig5){ref-type="fig"}). Further sequence interrogation of this locus revealed that this ATAC-seq peak contains a ERE motif with one nucleotide mismatch (GGTCAnnnTGACa) from the consensus ERE ([Figure 5C](#fig5){ref-type="fig"}, lower panel). Given that ERE motifs found in prototypical ERα target genes, such as Oxytocin and pS2, contain one base mismatch from the consensus ([@bib23]), we next functionally validated the ERE in this locus. To this end, we first tested whether the DNA sequence of this region have E2- and ERα-responsive transcriptional activity. We cloned the 4 kb region of *Ern1* into a luciferase reporter plasmid, transfected into 293 T cells with or without a plasmid expressing ERα, and treated the cells with E2 or control vehicle and measured luciferase activity. This revealed that the *Ern1*(−4 kb) construct has E2- and ERα-responsive transactivating capacity ([Figure 5D](#fig5){ref-type="fig"}). Importantly, this E2- and ERα-responsive transactivating capacity was diminished when the ERE was mutated in the *Ern1*(−4 kb) construct, indicating that the ERE located upstream of *Ern1* is functional. To determine if ERα binds to this locus in primary hematopoietic progenitor cells, we performed ChIP-qPCR. c-kit^+^ HSPCs were isolated from oil- or E2-treated mice and were subject to ChIP. We found that the ERα occupancy at peak 2 increased significantly upon E2 treatment ([Figure 5E](#fig5){ref-type="fig"}). This result coincides with our finding that this locus becomes more accessible upon E2 treatment and that it contains a functional ERE. These results establish that *Ire1α* is a direct target of ligand-activated ERα in hematopoietic progenitor cells.

![ERα Associates with the *Ire1α* Upstream Locus in HSPCs (**A**) Metagene analysis indentifying differentially expressed peaks in E2 treated HSPCs.\
(**B**) Homer motif analysis. Both de novo (unsupervised) and supervised motif-identifying algorithms classified EREs as the most enriched motif in E2-treated HSPCs. (**C**) Representative gene track of *Ire1α* with peaks identified from ATAC-Seq. Three peaks were identified upstream of the *Ire1α* promoter (denoted Peak 1, 2, and 3). Peak two was identified as differentially upregulated in E2 treated cells, and contains a ERE motif (lower panel, purple) with one nucleotide mismatch with the consensus ERE (shown in red). Primers were designed for each peak and are denoted P1, P2, and P3. (**D**) Luciferase reporter assay. A 4 kb genomic sequence of *Ire1α* regulatory elements containing peaks 1--3 was cloned into pGL2 Basic plasmid. 293 T cells were transfected with the reporter plasmids, ERα expressing or an empty vector, and a control renilla luciferase plasmid. Cells were treated with E2 for 20 hr and luciferase activity measured. A significant increase in the luciferase activity was observed with the Ire1α construct in an E2- and ERα-dependent manner, and this response was abolished by mutating the ERE. (n = 4 independent experiments, two technical replicates per condition) \*\*\*p\<0.001; \*p\<0.05, ANOVA (**E**) ChIP qPCR was conducted for the three peaks identified by ATAC-Seq using primers shown in (**C**). y-axis represents the relative value to percent input in Oil or E2 treated cells. (n = 4; two independent experiments, two biological replicate) \*\*p\<0.01; Student's t-test.](elife-31159-fig5){#fig5}

Estradiol promotes protective unfolded protein response in HSCs {#s2-6}
---------------------------------------------------------------

The UPR was recently shown to regulate cellular responses in HSPCs upon proteotoxic stresses ([@bib44]; [@bib74]). Upon ER stress, human HSCs upregulated the pro-apoptotic PERK branch of the UPR, thus causing cell death, whereas downstream progenitors upregulated the pro-survival IRE1α-XBP1 branch to survive ([@bib74]). We hypothesized that E2 stimulation upregulates the pro-survival Ire1α-Xbp1 branch in HSCs, thus endowing them with resistance to various cellular stressors. To test this theory, we induced ER stress in vitro in freshly isolated LSK cells from oil- or E2-treated mice with the drugs tunicamycin and thapsigargin. Cells were then analyzed for viability using Annexin V staining and colony assays. Both tunicamycin and thapsigargin increased the frequencies of Annexin V^+^ LSK cells ([Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}) and reduced clonogenicity ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). However, in vivo E2 treatment significantly rescued these effects, indicating that HSPCs exposed to E2 are protected from proteotoxic stress. These results establish that the E2-ERα pathway confers resistance against ER stress, paralleling the activation of the protective Ire1α-Xbp1 branch of the UPR.

Increased oxidative stress, such as that caused by ionizing irradiation, can cause protein oxidation, leading to accumulation of protein aggregates, which in turn elicits ER stress and activates the UPR ([@bib4]; [@bib39]; [@bib67]). We thus examined whether the total body irradiation we used in the previous experiments affected proteostasis of hematopoietic cells. We quantified protein aggregates using a recently published protocol ([@bib62]), and observed a dose-dependent increase in the levels of protein aggregates following sublethal doses of irradiation ([Figure 6A](#fig6){ref-type="fig"}). Interestingly, E2-treatment significantly reduced the levels of protein aggregates after TBI in LSK cells but not WBM cells, in concordance with the induction of *Ire1α* and splicing of *Xbp1* ([Figure 6B](#fig6){ref-type="fig"}).

![Estrogen Mitigates Proteotoxic Stress in HSPCs (**A**) Representative FACS plots of Proteostat staining in LSK cells from mice subjected to various doses of radiation.\
(**B**) Proteostat staining revealed that irradiation induces protein aggregation in all hematopoietic cell types, and E2 reduces aggregation in immature progenitor cells. Mice were treated with oil or E2 for 1 week followed by a single dose of radiation (IR: 400cGy) or unirradiated (ctrl), and analyzed 16 hr later by flow cytometry (n = 5, three independent experiments). \*p\<0.05, two-way ANOVA (**C**) c-kit^+^ progenitor cells were electroporated with Cas9 protein with sgRNAs against either *Rosa26* (**R26**) or three different sgRNAs against *Ire1α*. Cells were collected after 48 hr and analyzed by immunoblotting. (**D**) Deletion of *Ire1α* by the CRISPR/Cas9 system sensitized LSK cells to ER stressors. LSK cells from oil- or E2-treated mice were gene edited as in (**C**), incubated overnight with ER stressors, and plated on semi-solid media for colony formation. (n = 3 independent experiments) \*p\<0.05, two-way ANOVA (**E**) 2000 gene-edited LSK cells (*Rosa26* (n = 14, Oil; n = 14, (**E2**) or *Ire1α* (n = 14, Oil; n = 11, E2; four independent experiments) were transplanted into lethally irradiated recipients, followed by oil or E2 administration every other day. Shown are blood counts 14 days after transplantation. \*p\<0.05; \*\*\*p\<0.001; Kruskal Willis with Dunn's multiple comparisons test. (**F**) LSK and (**G**) myeloid progenitor (MP) frequencies were measured in recipients of gene-edited LSKs. (n = 5, two independent experiments) \*p\<0.05, two-way ANOVA. In (**E--G**), Ire1α sgRNA 2 + 3 or 1 + 2 + 3 was used with similar results. All data represent mean ±standard deviation.](elife-31159-fig6){#fig6}

We then tested whether the Ire1α-Xbp1 branch is required for the E2-ERα pathway to endow HSCs with stress resistance. Using our recently described mouse and human HSPC genome editing protocol ([@bib24]), we designed multiple single-guide RNAs (sgRNAs) against Ire1α, and electroporated them as a ribonucleoprotein (RNP) complex with Cas9 protein into LSK cells. By immunoblotting and sequencing, we identified sgRNAs that efficiently ablated Ire1α ([Figure 6C](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). These sgRNAs were used in subsequent experiments. We isolated LSK cells from both oil- and E2-treated mice, and electroporated them with Cas9-RNPs with sgRNAs against *Ire1α* or control *Rosa26*. Clonal analysis of electroporated LSK cells indicated that about 25% of the clones had deletions between the two sgRNA target sites, while another 50% of the clones had small indels detected by TIDE analysis ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). The bulk-modified cells were then plated in media with or without ER stressors. Strikingly, we found that deleting *Ire1α* abolished the resistance endowed by E2 against ER stressors ([Figure 6D](#fig6){ref-type="fig"}). These results demonstrate that E2 promotes ER stress resistance by activating the cytoprotective UPR branch governed by the Ire1α-Xbp1 pathway.

Finally, we tested whether the induction of the Ire1α-Xbp1 pathway by ERα promotes hematopoietic regeneration. LSK cells were electroporated with Cas9-RNP targeting either Rosa26 or Ire1α and transplanted into lethally irradiated mice. Recipients were treated with control oil or E2 every other day, and peripheral blood was collected at day 14 post-TBI. Consistent with our previous findings ([Figure 2D--F](#fig2){ref-type="fig"}), recipients of Rosa26-edited LSK cells demonstrated enhanced hematopoietic recovery when treated with E2, which was largely suppressed when Ire1α was deleted ([Figure 6E](#fig6){ref-type="fig"}). We also investigated the regeneration of HSPCs in the bone marrow of these recipient mice. The frequencies of LSK and myeloid progenitor cells were significantly increased in mice receiving E2 treatment after transplantation ([Figure 6F--G](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1E--F](#fig6s1){ref-type="fig"}). However, this effect was abolished in similarly treated recipients of Ire1α*-*edited LSK cells. Collectively, these results demonstrate that the E2-ERα module activates and at least partly depends on the Ire1α-Xbp1 pathway to promote hematopoietic regeneration.

Discussion {#s3}
==========

Our results establish that E2 activates the Ire1α-Xbp1 branch of the UPR in HSCs through ERα, thus augmenting hematopoietic regeneration. E2 treatment increased the capacity of HSCs to reconstitute the hematopoietic system upon transplantation and accelerated hematopoietic regeneration after total body irradiation. E2-ERα signaling transcriptionally induced the expression of Ire1α, which then promoted the splicing of *Xbp1* mRNA to induce Xbp1s, a transcription factor critical for the UPR. The importance of the Ire1α-Xbp1 pathway-mediated UPR is exemplified by our finding that E2 augments hematopoietic recovery after transplantation through Ire1α. Thus, E2 is a soluble long-range signal that promotes hematopoietic regeneration at least partly by inducing a cytoprotective UPR in HSCs.

Whether activation of the UPR is beneficial or detrimental for HSC function appears to depend on which pathway becomes activated and to what extent it is activated. Uncontrolled activation of the UPR, particularly of the PERK pathway, has been shown to impair HSC function. Deletion of Grp78 (BiP) in mice activates all three branches of the UPR and reduces the HSC pool, causing lymphopenia ([@bib78]). Human HSCs activate the PERK pathway upon proteotoxic stress, rendering them susceptible to apoptosis ([@bib74]). On the other hand, activation of the Ire1α-Xbp1 branch or the protein folding capacity improves HSC function. While human HSCs activate the PERK pathway upon proteotoxic stress and undergo apoptosis, downstream progenitors activate the Ire1α-Xbp1 pathway to survive ([@bib74]). Additionally, overexpression of a molecular chaperone ERDJ4 (encoded by *DNAJB9*) protects human HSCs from proteotoxic stress and increases the reconstitution capacity ([@bib74]). Our results are consistent with the model that activation of the Ire1α-Xbp1 branch by E2 protects HSCs from proteotoxic stress and promotes hematopoietic regeneration, although we cannot formally exclude the possibility that two other UPR branches (PERK and ATF6) are also involved. IRE1 also promotes decay of mRNA localized to the ER, called regulated IRE1-dependent decay of mRNA (RIDD) ([@bib40]). However, RIDD seems unlikely to be activated in E2-treated HSCs since translation is not attenuated in HSCs after E2 exposure. Furthermore, RIDD is usually associated with apoptotic cell death, which is not observed in E2-treated cells. It is important to note that Xbp1 is largely dispensable for HSC maintenance during homeostasis ([@bib5]), indicating that although Xbp1 is not required for the homeostatic maintenance of HSCs, its activation provides additional protection against proteotoxic stress. Thus, selective activation of the Ire1α-Xbp1 pathway is key to harnessing the UPR to improve hematopoietic regeneration. How E2 preferentially activates the Ire1α-Xbp1 branch without appreciable activation of the PERK and ATF6 pathways remains to be explored.

Consistent with our previous finding that E2 promotes division of HSCs ([@bib46]), we found that E2-treated HSCs had increased expression of genes known as Myc target genes, some of which were induced in vitro after E2 stimulation. It is important to note, though, that although some of the Myc targets were induced, c-Myc, N-Myc, or L-Myc were not induced by E2. Thus, to what extent the global upregulation of Myc-target genes in HSCs after E2 treatment reflects Myc-induced responses or an indirect consequence of the activated cell cycle remains unclear. More work is needed to determine the direct target of the E2-ERα module that promotes HSC division.

Our findings indicate that E2 promotes hematopoietic regeneration by protecting HSPCs from irradiation-induced stress. An earlier study reported that female mice are more resistant to acute irradiation than male mice, and that the estrus cycle affects radioresistance ([@bib54]), although careful interpretation is required since strain differences also contribute to radioresistance ([@bib22]). Estrogenic compounds such as genistein have also been known to have radioprotective effects ([@bib25]). Additionally, it has been demonstrated that engraftment of human HSPCs is more efficient in female recipient mice than male mice ([@bib49]). The mechanism behind this sexual difference in HSC engraftment remains to be established, but it is tempting to speculate that the female hormonal milieu protects engrafting HSCs from stress. Further investigation on how estrogens, or more broadly hormones, prepare the recipient to accommodate transplanted HSCs, including the involvement of the bone marrow niche, may pave the way to improve the efficacy of bone marrow transplantation. Since estrogens also have detrimental hematopoietic side-effects, such as causing thromboembolism ([@bib72]), future studies should aim to separate the beneficial effects of estrogens on HSC function from other negative effects.

In concordance with the effect of E2 on HSPC regeneration, E2 also improved the blood cell counts after irradiation or transplantation, although the effects of E2 on mature cells in the blood were less pronounced than the effects on HSPCs. We postulate that since production of mature cells involves multiple intermediate cell stages during differentiation and that it is also affected by a variety of homeostatic mechanisms (such as thrombopoietin production by the liver and the kidney), the end output in the blood may not be as robust as the effects on HSPCs.

More broadly, our data extend the role of systemic UPR activation to regeneration by adult stem cells. Exciting new data have described that the UPR is a key pathway in intercellular and inter-tissue communication regulating tissue homeostasis and aging. Chemical chaperones, such as osmolytes and hydrophobic compounds, aid in cellular protein folding capacity to maintain proteostasis, and have therapeutic potential in treating metabolic and neurodegenerative diseases ([@bib14]). Interestingly, taurocholic acid, a chemical chaperone that is more abundant in the bile acid of fetal liver compared to adult liver, inhibits protein aggregation in fetal liver HSCs to support their rapid expansion during development and in culture ([@bib44]; [@bib62]). This illustrates that systemic factor(s) can affect the protein folding capacity of HSCs, although it remains unclear whether bile acid affects the UPR of HSCs in adult animals. In nematodes and fruit flies, impaired proteostasis of a cell type or a tissue can communicate to other cells to coordinate stress responses systemically by upregulating the UPR in the periphery ([@bib3]; [@bib75]). Additionally, activation of the UPR in neurons by Xbp1s expression extends lifespan of *C.elegans*, and strikingly, augments the UPR in the intestine through a cell non-autonomous mechanism involving an unknown neurotransmitter ([@bib71]). The Ire1α-Xbp1s pathway appears to be important for systemic UPR activation in vertebrates as well, since Xbp1s expression in murine POMC neurons activates Xbp1s in the liver, paralleling the improved hepatic insulin sensitivity and suppression of glucose production ([@bib79]). Thus, although the secreted systemic factors that activate the UPR in distal tissues remain largely unknown, the UPR is a conserved mechanism that is activated by systemic factors to prepare the perceiving cells against stress by promoting proteostasis. Our work establishes that E2 is a systemic extrinsic regulator of UPR in adult HSCs that endows them with enhanced stress resistance, which is critical during regeneration.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

The mouse alleles used in this study were *Ubc-GFP* (C57BL/6-Tg(UBC-GFP)30Scha/J, JAX Stock \#004353) ([@bib58]), *Mx1-Cre* (C.Cg-Tg(Mx1-cre)1Cgn/J, JAX Stock \#005673) ([@bib34]), *Esr1^fl^* ([@bib64]), and *ERAI* ([@bib29]) on a C57BL/6 background. Male mice were used for most experiments unless otherwise noted. Mice were housed in AAALAC-accredited, specific-pathogen-free animal care facilities at Baylor College of Medicine (BCM), or University of Michigan (UM) with 12 hr light-dark cycle and received standard chow ad libitum. All procedures were approved by the BCM (protocol \#AN-5858) or UM (protocol \#PRO00007786) Institutional Animal Care and Use Committees.

Drug and chemical treatments {#s4-2}
----------------------------

Mice were injected subcutaneously with 100 μl of corn oil containing 2 μg estradiol (Sigma, St. Louis, MO) every day for 7 days unless otherwise noted. Oil treated mice and E2 treated mice were caged separately. Poly I:C (Amersham, Piscataway, NJ) was resuspended in PBS at 50 μg/ml, and mice were injected intraperitoneally with 0.5 μg/gram of body mass every other day for 6 days. To measure protein translation, mice were injected intraperitoneally with 500 μg of puromycin (ThermoFisher Scientific, Waltham, MA) and sacrified one hour later. To promote HSC activation and mobilization, mice were intraperitoneally injected with 4 mg of cyclophosphamide (Bristol Myers Squibb, NY) on day −1, and then injected subcutaneously on successive days with 5 μg of human G-CSF (Amgen, Thousand Oaks, CA). Mice were sacrificed on day 3 or 6.

Radiation studies {#s4-3}
-----------------

10- to 12-week-old male C57BL/6 mice were treated for 7 days with control oil or E2 followed by whole body irradiation at 600 cGy TBI using a cesium-137 irradiator. PB complete blood counts (CBC) were measured using a scil Vet abc Plus+ (scil Animal Care/Henry Schein Animal Health, Gurnee, IL) every other day. For assessment of hematopoietic content, 10- to 12-week-old male C57BL/6 mice were treated for 7 days with control oil or E2 followed by whole body irradiation at 600 cGy TBI and were euthanized at one or two weeks post-irradiation. For survival studies, 10- to 12-week-old C57BL/6 mice were irradiated with 800 cGy TBI after E2 regimen. An IACUC-approved protocol (AN-5858) was followed to monitor the survival of irradiated mice.

Transplantation {#s4-4}
---------------

10--12 week-old male C57BL/6 mice were randomly assigned to groups after receiving two doses of radiation (500 cGy) administered at least three hours apart (total 1000 cGy). 100 GFP^+^ HSCs were co-transplanted with 2 × 10^5^ GFP^-^ WBM cells into each recipient (total volume of 100 ul; 1X HBSS, 2% heat-inactivated bovine serum). Injections were administered via retroorbial injection. For secondary transplantation, similarly irradiated recipients were injected with 2 million WBM cells from primary recipients (sacrificed at 16 weeks post-transplantation).

Flow-cytometry and HSC isolation {#s4-5}
--------------------------------

Bone marrow cells were either flushed from the long bones (tibias and femurs) or isolated by crushing the long bones (tibias and femurs), pelvic bones, and vertebrae with mortar and pestle in Hank's buffered salt solution (HBSS) without calcium and magnesium, supplemented with 2% heat-inactivated bovine serum (GIBCO, Grand Island, NY). Cells were triturated and filtered through a nylon screen (100 μm, Sefar America, Kansas City, MO) or a 40 μm cell strainer (Fisher Scientific, Pittsburg, PA) to obtain a single-cell suspension. For isolation of CD150^+^CD48^−/low^Lineage^−^Sca-1^+^c-kit^+^ HSCs ([@bib33]; [@bib51]), bone marrow cells were incubated with PE-Cy5-conjugated anti-CD150 (TC15-12F12.2; BioLegend, San Diego, CA), PE-conjugated (HM48-1; BioLegend) or PE-Cy7-conjugated anti-CD48, APC-conjugated anti-Sca-1 (Ly6A/E; E13-6.7), and biotin-conjugated anti-c-kit (2B8) antibody, in addition to antibodies against the following FITC-conjugated lineage markers: CD41 (MWReg30; BD Biosciences, San Jose, CA), Ter119, B220 (6B2), Gr-1 (8C5), CD2 (RM2-5), CD3 (KT31.1), and CD8 (53--6.7). For the isolation of GFP^+^ HSCs, the FITC channel was left open and PE-conjugated lineage markers were used instead. For isolation of CD34^-^CD16/32^−^Lineage^−^Sca-1^-^c-kit^+^ MEPs, CD34^+^CD16/32^−^Lineage^−^Sca-1^-^c-kit^+^ CMPs, and CD34^+^CD16/32^+^Lineage^−^Sca-1^-^c-kit^+^ GMPs, bone marrow cells were incubated with FITC-conjugated anti-CD34 (RAM34; eBiosciences, San Diego, CA), PE-Cy7 conjugated anti-CD16/32 (93; Biolegend), PE-Cy5-conjugated anti-Sca-1 (Ly6A/E; E13-6.7), and biotin-conjugated anti-c-kit (2B8) antibody, in addition to antibodies against the following PE-conjugated lineage markers: Ter119, B220 (6B2), Gr-1 (8C5), Mac-1 (M1/70), CD2 (RM2-5), CD3 (KT31.1), and CD8 (53--6.7). Unless otherwise noted, antibodies were obtained from BioLegend, BD Biosciences, or eBioscience (San Diego, CA). Biotin-conjugated antibodies were visualized using streptavidin-conjugated APC-Cy7. HSCs were sometimes pre-enriched by selecting c-kit^+^ cells using paramagnetic microbeads and autoMACS (Miltenyi Biotec, Auburn, CA). Nonviable cells were excluded from sorts and analyses using the viability dye 4\',6-diamidino-2-phenylindole (DAPI) (1 μg/ml). To analyze hematopoietic lineage composition, bone marrow cells or splenocytes were incubated with PerCPCy5.5-conjugated anti-B220, PE-conjugated anti-Ter119, APC-conjugated anti-CD3, APC-eFluor780-conjugated anti-Mac-1 (M1/70), and PE-Cy7-conjugated anti-Gr-1 antibodies. Annexin V staining was performed using Annexin V APC (BD Biosciences). For analysis of aggregated proteins, hematopoietic cells were stained with anti-c-kit, Sca-1, and lineage antibody mix and then fixed in Cytofix/Cytoperm Fixation and Permeabilization Solution (BD Biosciences) for 30 min. Fixed cells were then stained with the ProteoStat dye (1:10,000 in permeabilization solution) at 25°C for 30 min (Enzo Life Sciences, Farmingdale, NY). To measure protein translation in HSCs, bone marrow cells were stained for HSC markers, and then fixed/permeabilized using BD Cytofix/Cytoperm solution. Cells were incubated with anti-puromycin antibody (12D10, Millipore, Billerica, MA) diluted in BD Perm/Wash Buffer (BD Biosciences) at 1:200 for one hour at room temperature. Cells were washed once and incubated with Alexa Fluor 633-conjugated anti-mouse IgG2a antibody (ThermoFisher Scientific, Waltham, MA) for 30 min at room temperature, washed once, and stained with DAPI before analyzing by flow cytometry. Flow cytometry was performed with FACSAria II, FACSCanto II, LSR II, or LSRFortessa flow-cytometers (BD Biosciences).

Quantitative real-time (reverse transcription) PCR {#s4-6}
--------------------------------------------------

HSCs and other hematopoietic cells were sorted into Trizol (Life Technologies, Carlsbad, CA) and RNA was isolated according to the manufacturer\'s instructions. cDNA was made with random primers and SuperScript III reverse transcriptase (ThermoFisher Scientific, Waltham, MA). Quantitative PCR was performed using a ViiA7 Real-Time PCR System (ThermoFisher Scientific, Waltham, MA). Each sample was normalized to β-actin. Data were analyzed using the 2^-ΔΔct^ method. Primers to quantify cDNA levels are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. Analysis of spliced:unspliced XBP1 ratios were conducted with the Taqman probes spliced XBP1 5' 6-FAM/TGCTGAGTC/ZEN/CGCAGCAGGTGCA/IABkFQ-3' and unspliced XBP1 5'-HEX/CGCAGCACT/ZEN/CAGACTATGTGCACC/IABkFQ-3'. As an endogenous control, the Gapdh primer and probe assay (Applied Biosystems, ID no. Mm99999915_g1) was used. cDNA was amplified using TaqMan Universal PCR Master Mix Kit (ThermoFisher Scientific, Waltham, MA) according to the manufacturer's instructions.

RNA-seq {#s4-7}
-------

HSCs were sorted into Trizol and RNA purified according to the manufacturer\'s instructions. DNase I treated RNA samples were amplified using the NuGEN Ovation RNA-Seq System (NuGEN, San Carlos, CA), and cDNA fragmented using a Covaris Ultrasonicator (Covaris, Woburn, MA). Fragmented cDNA was assembled into a sequencing library using KAPA Library Preparation Kit for Ion Torrent (KAPA Biosystems, Wilmington, MA) and sequenced on an Ion Proton Sequencer (ThermoFisher Scientific, Waltham, MA). Reads obtained from Ion Torrent sequencing were mapped to mm10 using STAR (version 2.5.2b \[[@bib17]\]), which was followed by differential expression analysis using DESeq2 (version 1.12.4 \[[@bib38]\]). Pairwise GSEA (GSEA, version 2.2.1 \[[@bib68]\]) was performed, combinatorially, on the lists of differentially expressed genes derived from each comparison.

ATAC-seq {#s4-8}
--------

ATAC-seq library was performed essentially as described in [@bib8], with some modifications. 5000 HSCs were sorted and incubated in 100ul lysis buffer (10 mM Tris-Cl, pH 7.4, 10 mM NaCl, 3 mM MgCl2 and 0.1% NP-40) for 3 min on ice. Immediately after lysis, the lysis buffer was removed by spinning at 500 x g for 5 min with 4^o^C table-top centrifuge. The nuclei pellet was then resuspended in 10μl of transposase reaction mix (2μl 5xTAPS buffer (50mM TAPS-NaOH, 25mM MgCl~2~ (pH8.5)), 0.5μl Tn5 (0.885 mg/mL), 7.5μl of nuclear free water). The transposase reaction was incubated at 37^o^C for 30 min, and then stopped by adding 5μl of 0.2% SDS for 5 min at room temperature. The transposase reaction was then purified by a ZYMO DNA purification kit. Tagmentated DNA was eluted in 10μl nuclease free water, and a half of the elution volume was then used for PCR enrichment reaction with NEBNext Q5 Hot Start HiFi PCR Master Mix (NEB M0543S). The library amplification reaction included 25μl of 2x Q5 master mix, 5 μl of tagmentated DNA template, 2.5μl of 25uM PCR primer 1 (final conc. 1.25μM), 2.5μl of 25μM barcoded PCR primer (final conc. 1.25μM) (all primers from SIGMA), and 15μl of nuclear free water. PCR protocol was 5 min at 72^o^C, 30 sec at 98^o^C, and then n cycles of 10 sec at 98^o^C, 30 sec at 63^o^C, 1 min at 72^o^C, where "n" was determined by qPCR with SYBRGreen to reduce GC and size bias. After that, the library was purified using SPRI beads and eluted in 20μl of nuclear free water (the final concentration \~ 30nM). Libraries were sequenced on the Illumina HiSeq 2000 platform. Reads were mapped to mm10 using Bowtie2 (Version: 2.2.6), and peaks were called on each sample individually using MACS2 (Version: 2.1.0.20151222). Differential peaks were obtained on overlapping peaks using PePr (Version: 1.1.18). Heatmaps were generated using deepTools computeMatrix algorithm whereby the center each location (from BED file) was used as the reference point and was extended ± 5kb from the center point. 

HSC culture and differentiation assays {#s4-9}
--------------------------------------

For CFU assays, single freshly isolated HSCs from control and E2-treated *Esr^fl/fl^*and *Esr^fl/fl^; Mx1-Cre* mice were plated into 96-well plates containing M3434 MethoCult methylcellulose media (StemCell Technologies, Cambridge, MA). Colonies were collected, washed, and cytospun onto glass slides followed by Wright-Giemsa staining. For megakaryocyte differentiation assays 24 single HSCs were sorted directly into serum free, phenol red free medium (X-Vivo 15, Lonza, Allendale, NJ) supplemented with 50 ng/ml of SCF and TPO, and 10 ng/mL IL-3 and IL-6 (all from Peprotech, Rocky Hill, NJ), and cultured for three days. Following brief culture, the contents of all wells were combined and plated on collagen-based MegaCult media (StemCell Technologies, Cambridge, MA) in duplicate. 10 days after plating, collagen slides were dehydrated and stained for cholinesterase activity per the manufacturer's instructions. Analysis of chemically-induced UPR was performed by sorting freshly isolated LSK cells (1 x 10^4^) into X-Vivo 15 supplemented with 1% FBS, 50ng/mL SCF and TPO, and 10ng/mL IL-3 and IL-6. Cells were incubated for 16 hours in 5% CO~2~ with combinations of vehicle (ethanol, final concentration 0.1%), E2 (200 μM), DMSO (final concentration 0.001%), tunicamycin (0.6 μg/ml in DMSO), and thapsigargin (4 nM in DMSO). Cells were collected, washed, and plated on methylcellulose media for CFU assays.

Immunohistochemistry {#s4-10}
--------------------

Femurs from control and E2-treated mice were fixed overnight in 4% paraformaldehyde and then decalcified in 10% EDTA for 3-4 days, embedded in 8% gelatin to prepare 6 μm sections. Slides were incubated with rat anti-CD41 antibody (eBioscience, San Diego, CA) diluted 1:500 in blocking buffer (4% goat serum, 0.4% BSA, 0.1% NP-40 in PBS) overnight at 4 °C. Slides were rinsed and incubated with Alexa Fluor 488-conjugated goat anti-rat antibody (ThermoFisher Scientific, Waltham, MA) at 1:500 dilution in blocking buffer containing DAPI. Images were obtained using a Leica DMI 6000B microscope.

Immunoblotting {#s4-11}
--------------

Immunoblotting was performed as described previously ([@bib47]). Briefly, the same number of cells (20,000-30,000) from each test population were sorted into Trichloroacetic acid (TCA) and adjusted to a final concentration of 10% TCA. Extracts were incubated on ice for 15 minutes and spun down for 10 minutes at 13,000 rpm at 4°C. The supernatant was removed and the pellets were washed with acetone twice then dried. The protein pellets were solubilized with Solubilization buffer (9 M Urea, 2% Triton X-100, 1% DTT) before adding LDS loading buffer (Invitrogen, Carlsbad, CA). Proteins were separated on a Bis-Tris polyacrylamide gel (ThermoFisher Scientific, Waltham, MA) and transferred to a PVDF membrane (Millipore, Billerica, MA). Antibodies were anti-Ire1α (Cell Signaling Technology, 3294), anti-Xbp1s (Biolegend, Poly6195), and anti-ß-actin (A1978, Sigma). 

Cell lines {#s4-12}
----------

293T cells were obtained from ATCC (CRL-3216) and were tested negative for mycoplasma contamination. 

Luciferase assay {#s4-13}
----------------

Approximately 4kb upstream of the Ire1α TSS was cloned into pGL2 Basic. ERα was expressed from pcDNA-HA-ER WT (Addgene \#49498). 293T cells were transfected with the indicated combination of the plasmids in OptiMEM (Invitrogen, Carlsbad, CA). 6 hours after transfection, the media was replaced with phenol red free X-vivo15 media supplemented with 10% charcoal-stripped FBS (Invitrogen, Carlsbad, CA). Cells were treated with or without 10^-7^M of E2 dissolved in ethanol for 20 hours before cells were harvested for luciferase activity measurement performed according to the manufacturer's instruction (Promega, Madison, WI). 

ChIP assays {#s4-14}
-----------

Cells were fixed with 1% paraformaldehyde for 10 minutes at room temperature. 125 mM glycine was then added and incubated at room temperature for 5 minutes. Cells were collected at 500 x g for 10 minutes at 4°C and washed twice with PBS. The pellet was lysed in Nuclear Lysis Buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1% SDS, 1x protease inhibitors (Roche) for 20 minutes on ice. Samples were then diluted with PBS to bring SDS concentration to 0.25% and sonicated in a Bioruptor for 23 minutes (settings: High, 30 seconds on and 30 seconds off). Lysates were diluted 1:1.5X with equilibration buffer (10mM Tris, 233 mM NaCl, 1.66 % TritonX-100, 0.166 % sodium deoxycholate, 1 mM EDTA, inhibitors) and centrifuged at 14,000 x g, 4°C for 10 minutes. Supernatant was transferred to a new tube (10% of the sample was saved as input). ERa (ab32063, Abcam, Cambridge, MA) and IgG antibodies were added to the lysate and incubated at 4°C overnight. Protein A/G Dynabeads (ThermoFisher Scientific) were added to the chromatin and incubated for 2 hours at 4°C. Beads were washed subsequently with RIPA-LS (10 mM Tris-HCl/pH 8.0, 140 mM NaCl, 0.1% SDS, 1% Triton X-100, 1 mM EDTA, 0.1% sodium deoxycholate) for 3 times, RIPA-HS (10 mM Tris-HCl/pH 8.0, 500 mM NaCl, 0.1% SDS, 1% Triton X-100, 1 mM EDTA, 0.1% sodium deoxycholate) for 3 times, RIPA-LiCl (10 mM Tris-HCl/pH 8.0, 1 mM EDTA, LiCl 250mM, 0.5% NP-40, 0.5% sodium deoxycholate) for 3 times, and 10 mM Tris-HCl, pH 8.0 for 3 times, after of which samples were transferred to a new tube. Beads were then incubated with 50 μl elution buffer (0.5% SDS, 300 mM NaCl, 5 mM EDTA, 10 mM Tris HCl pH 8.0) containing 2 μl of 10 mg/ml Proteinase K for 1 hour at 55°C and 8 hours at 65°C to reverse crosslink, and supernatant was transferred to a new tube. Another 20 μl of elution buffer and 1 μl of Proteinase K were added to the beads and incubated for 1h at 55°C, and the supernatants were combined. Finally, DNA was purified with SPRI beads and used for qPCR with primers listed in Supplementary File 1. 

CRISPR/Cas9-mediated genome editing {#s4-15}
-----------------------------------

Genome editing was performed essentially as described previously ([@bib24]). Briefly, protospacer sequences for each target gene were identified using the CRISPRscan algorithm (www.crisprscan.org). DNA templates for sgRNAs were made in a PCR reaction using a forward primer containing a T7 promoter, a reverse primer specific for the 3' end of the improved scaffold, and pKLV-U6gRNA-EF(BbsI)-PGKpuro2ABFP plasmid (Addgene \# 62348). c-kit^+^ or LSK cells were isolated by MACS or FACS, respectively, and cultured in X-Vivo 15 (Lonza, Allendale, NJ) supplemented with 50 ng/ml of SCF and TPO, and 10 ng/mL IL-3 and IL-6 (all from Peprotech, Rocky Hill, NJ) for 1 hour. 1x10^4^ to 1x10^5^ c-kit^+^ cells or 5x10^4^ LSK cells were resuspended into 10 μl of Buffer T (Invitrogen), mixed with 1 μg sgRNA and 1 μg Cas9 protein (PNA Bio), and electroporated using a Neon transfection system (ThermoFisher Scientific) using the following parameters; 1700V, 20ms, 1 pulse. After overnight culture in X-Vivo media, live cells were sorted and used for subsequent experiments. For clonal analysis of editing efficiency, single LSK cells were sorted into M3434 MethoCult methylcellulose media (StemCell Technologies, Cambridge, MA) after electroporation. Colonies were collected 12 days later, and purified genomic DNA was sequenced via Sanger sequencing. Indels were quantified using the TIDE deconstruction algorithm ([@bib7]). See Supplementary File 1 for oligo sequence.

Quantification and statistical analysis {#s4-16}
---------------------------------------

Statistical analyses were performed using GraphPad Prism 5.0c (GraphPad Software Inc., San Diego, CA). To ensure the reproducibility of our findings, all data were derived from multiple independent experiments performed on different days. Sample sizes were chosen based on observed effect sizes and standard errors from previous experiments, and data was checked for normality and similar variance between groups. Only males were used in these studies, and all experimental units were age-matched. In the case of investigating ERα deletion, untreated floxed littermates were used as controls. Animal studies were performed without blinding. To test statistical significance of the means of two samples, two-tailed Student's t tests or Mann Whitney U Tests were performed. Statistical significance of multiple groups was evaluated with a two-way ANOVA or repeated measures ANOVA followed by Bonferroni's test for multiple comparisons. Analysis of three or more groups with unequal sample sizes was conducted using the Kruskal-Wallis H Test followed by Dunn's multiple comparisons test. Survival curves were tested for statistical significance with a log-rank test. A p-value of less than 0.05 was considered significant. Values are reported as mean ± SD unless stated otherwise. 

Data and software availability {#s4-17}
------------------------------

The accession number for the RNA sequencing data reported in this paper is GSE99120. The accession number for the ATAC-seq data is SRP12895.
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###### List of primers used for quantitative real-time PCR, ChIP-seq, and sgRNA systhesis.

All primers are listed in the 5' to 3' direction.

10.7554/eLife.31159.016

Major datasets {#s7}
--------------

The following datasets were generated:

Daisuke NakadaRichard H ChappleKevin A Hoegenauer2017ATAC-Seq of hematopoietic stem cells from vehicle and estrogen-treated mice<https://www.ncbi.nlm.nih.gov/sra/SRP128950>Publicly available at NCBI BioProject (Accession no: SRP128950)

Nakada DChapple RHoegenauer KA2017RNA-Seq of hematopoietic stem cells from vehicle and estrogen-treated mice<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99120>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE99120).
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Decision letter

Lo Celso

Cristina

Reviewing Editor

Imperial College London

United Kingdom

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for sending your article entitled \"ERα promotes hematopoietic regeneration through the Ire1α-mediated unfolded protein response\" for peer review at *eLife*. Your article has been evaluated by Marianne Bronner (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

Main concerns raised relate to the link between ER, IRE1 and target genes such as Myc.

1\) Regarding knocking down IRE1, please see reviewer 2 point 2 and reviewer 3 point 4.

2\) Regarding the link between ER and IRE1, please see reviewer 1 point 3 and reviewer 3 point 3.

3\) Regarding the effect on target genes, including Myc, please see reviewer 1 point 2 and reviewer 2 point 2.

Moreover, there was agreement on the need to further clarify the cell autonomous/non-autonomous action of E2, including a deeper discussion of the consistency of results (see reviewer 1 point 1 and reviewer 3 point 1.

Addressing the other points raised would of course be beneficial; however there is a concern that addressing the two major concerns may require mouse models or time course experiments that might require a longer timeframe of revision than normally allowed by *eLife*.

*Reviewer \#1:*

1\) The authors investigate in detail the role and mechanism of action of estrogen stimulation on hematopoietic stem cells, and perform important transplantation experiments that were missed in previous studies. Linking the UPR to the E2 response is very novel and a finding that advances not only the HSC field.

The overall work is very good and elegant, however my major concern is the repeated comment that ER works cell intrinsically only. It certainly works within HSCs, however without any experiments with chimeric mice in which either the hematopoietic system or the stroma lack ERα it is impossible to conclude that ER signaling does not play a role indirectly through the stroma/ HSC niche too. In fact, some in vitro experiments only partially reproduce the in vivo findings, and in most experiments HSCs harvested from treated mice are used, rather than HSCs treated ex vivo. The authors could either generate the chimeras, which is however time-consuming as a pre-experiment, or be more careful in their comments.

2\) The other major missing point in terms of functional characterization of HSCs from E2-treated mice is a limiting dilution transplantation assay, so that not only groups of 100 HSCs, but also smaller doses, e.g. single or 5-10 HSCs can be assessed and frequencies can be estimated. This seems important especially in view of up-regulation of cMyc following E2 treatment, with Myc activation being consistently linked to loss of HSC function. Is it possible that E2 treatment leads to further proliferation of already active HSCs rather than dormant (e.g. label retaining) ones?

3\) Another major point regards the connection between ERα and the UPR. Is Ire1α a direct target of ERα? This could already be known, and therefore mentioned, or checked through bioinformatics analysis of the Ire1α promoter, and ideally a ChiP experiment.

4\) Finally, I don\'t see anywhere the gating strategy used to identify HSC and progenitor cell populations. It is very important that these are shown as different gates are used by different research groups and it is easy to be transparent about the gates used, as long as they are consistent throughout the work shown.

5\) The survival experiment described in [Figure 2](#fig2){ref-type="fig"} does not really add much to the previous experiment, showing recovery from a lower dose of irradiation. I would either remove the experiment entirely to avoid any reference to letting mice die as an experimental end point, which is unethical, or explain how the mice were humanely monitored.

Reviewer \#2:

In their manuscript \"ERα promotes hematopoietic regeneration through the IRE1α-mediated unfolded protein response\" Nakada et al. provide evidence that estrogen receptor (ER) signaling promotes HSC regeneration following irradiation at least in part due to activation of the Ire1a branch of the unfolded protein response (UPR). Altogether the hypothesis is interesting and the work is a nice extension of prior studies in this area.

I have a few major comments relating to improving the quality of the study:

1\) The implication of the data (and prior work from the Morrison lab) is that ER signaling promotes HSC proliferation. As such it would be important to distinguish whether the mechanism by which ER signaling promotes recovery is due to protection from apoptosis (given Annexin V data), proliferation or both, as either mechanism can lead to faster recovery of BM cell numbers.

2\) Along these lines, is UPR directly responsible for increased Myc/E2F gene levels and cell proliferation or vice versa? This can be tested in regenerative conditions using the CRISPR system developed by the authors and would define the epistatic relationship between these important and functionally interleaved gene programs in hematopoietic regeneration.

3\) Overall a key finding of the paper is the dependence on Ire1α based on CRISPR. To fully substantiate the Ire1α findings to the reader I recommend that the authors show the full timecourse of hematopoietic regeneration following IR such as shown in [Figure 2A](#fig2){ref-type="fig"}, and demonstrate by directly interrogating the BM whether similar kinetics of BM and LSK recovery are observed as in [Figure 3A-C](#fig3){ref-type="fig"}, at least looking in the donor compartment if not BM as a whole.

4\) [Figure 5F](#fig5){ref-type="fig"} shows sensitization of LSK to stressors; on the flipside does Ire1α KD also abrogate any increases in colony forming activity in LSK, or is the colony forming phenotype only specific to HSCs?

*Reviewer \#3:*

This study is an extension of a previous study showing E2 increases HSC proliferation and frequency and erythropoiesis (Nakada et al., 2014), showed E2 increases broad myelopoiesis, and uncovered the mechanistic link between E2 and UPR, a protective mechanism for HSCs (van Galen et al., 2014). They showed that IRE1-XBP1 branch of the UPR is responsible for E2\'s effect on HSCs, as deleting IRE1 using CRISPR in LSK cells blunted E2\'s effect on HSCs.

1\) Non-autonomous UPR refers to the phenomenon that ER stress in one tissue induces UPR in a remote tissue. If the authors claim that what they found here represents an example of non-autonomous UPR, they would need to show that ER stress in ovaries leads to release of E2, which activates UPR in HSCs. However, it does not seem to be the case here.

2\) The observation that E2 increases myelopoiesis but not lymphopoiesis is interesting. Do myeloid primed HSCs have increased ER stress than lymphoid primed HSCs? The authors propose IRE1 as an underlying mechanism. However, in [Figure 5G](#fig5){ref-type="fig"}, it appears that the effects of E2 and IRE1α are uncoupled. E2 increased WBC but IRE1α deletion had no effect on WBC. E2 had no effect on RBC but IRE1α deletion reduced RBC.

3\) The authors performed RNA-seq and found that UPR genes are upregulated in E2-treated HSCs. Importantly, they showed that the UPR upregulation upon E2 is dependent on ERα. How does E2-ERα upregulate IRE1? Does IRE1 promoter have ERα binding site? Does ERα bind to IRE1 promoter?

4\) In [Figure 5E](#fig5){ref-type="fig"}, what\'s the editing efficiency? Typically, a pool of CRISPR edited cells do not show knockdown, but need to be selected for single clones that have efficient knockdown. Since the novel aspect of this study is the connection of E2 with UPR and the knockout mouse models for all three branches of UPR are well established, it makes more sense to use the KO mice.

5\) The effect of E2 on hematopoiesis is inconsistent throughout the manuscript. e.g. in [Figure 2D-F, E2](#fig2){ref-type="fig"} significantly increases platelets. However, in [Figure 5G, E2](#fig5){ref-type="fig"} has no effect on platelets. It is unclear how robust the effect of E2 is.

6\) [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} is missing.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"ERα promotes murine hematopoietic regeneration through the Ire1α-mediated unfolded protein response\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Marianne Bronner (Senior Editor), and a Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

1\) Subsection "Estradiol promotes protective unfolded protein response in HSCs", third paragraph. Please state clearly that clonal analysis of electroporated LSK cells indicated that about 25% of the clones were deleted ([Figure 6](#fig6){ref-type="fig"}---figure -- supplement 1D). Nevertheless, bulk-modified cell populations used for subsequent experiments showed that....

2\) Subsection "Estradiol activates the unfolded protein response (UPR) pathway in HSCs", first paragraph. In line with the detailed explanation presented in the response letter, please modify the text to indicate that a number of Myc target genes were induced by E2, even though c-Myc, N-Myc and L-Myc were not. It would be helpful to include the comments provided in this section of the response letter within the Discussion section of the manuscript.

3\) Please indicate at least in the Materials and methods that, based on [Figure 1](#fig1){ref-type="fig"}---figure -- supplement 1A, HSCs were sorted as CD48-/low (and for brevity named CD48-) according to Kiel et al., Oguro et al. etc. There is much confusion in the field about where to place CD48 gates, and the more clarity is used in the presentations, the better. Overall, the gating schemes should include the experimental treatments and not just the control as presented in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. This is particularly true for readers who are evaluating how the E2 and IR treatment conditions change distribution of markers such as CD48 and CD150.

4\) Please include the comments about variable effects on platelets production presented in the response letter within the Discussion section.

10.7554/eLife.31159.023

Author response

> Main concerns raised relate to the link between ER, IRE1 and target genes such as Myc.
>
> 1\) Regarding knocking down IRE1, please see reviewer 2 point 2 and reviewer 3 point 4.

Regarding the efficiency of our CRISPR protocol, we have performed a clonal analysis of edited cells. We performed our CRISPR electroporation protocol outlined in our previously published manuscript (Gundry et al., 2016). Briefly, RNP complexes are assembled by co-incubating Cas9 protein and either 1 or 2 sgRNAs (Rosa26 and Ire1α respectively), and then delivered to LSKs via electroporation. We then sorted single LSKs into 96 well plates of methylcellulose medium to allow for colony formation. Clones were isolated and genomic DNA was profiled using Sanger sequencing. We then used a decomposition algorithm (TIDE) specifically designed to identify and quantify the major mutations at projected cut sites. The results of this analysis are highlighted in [Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}. We found that a large percentage (\>75%) of clones contained a mutation using this approach. Of those that were edited, one-third contained a large deletion consisting of an ablation of the DNA between the two sgRNA sites. The remaining colonies contained 1-4bp indels that were characterized as homozygous, heterozygous, or undetermined. Given the highly efficient editing of our technique, combined with our immunoblot results showing significant reduction in total Ire1α protein levels using this approach ([Figure 6C](#fig6){ref-type="fig"}), we concluded that this technique is sufficient for use in investigating the role of Ire1α in HSPCs.

In regards to the issue of whether "bulk" edited cells without selection of edited cells could be used to study the function of genes, we note that recent studies have used a similar "bulk" approach as we did. For example, Michael Kharas and colleagues deleted METTL3 from leukemia cell lines without selecting clones, and observed that METTL3 deletion reduced proliferation and survival in the bulk cell population (Nature Medicine. 23:1369). Ken Anderson and colleagues deleted KDM6B from multiple myeloma cells and observed reduced growth and survival of these cells (Leukemia. 31:2661).

Additionally, CRISPR dropout screens that have brought important insights into various area of biology depends on the principle that "bulk" edited cells with heterogeneous mutation profiles, even including some unedited cells, could be used to observe phenotypic changes, such as survival or gene expression changes (for example, Cell. 163:1515, Science. 350:1096, Cell Reports. 17:1193). These screens are performed by selecting cells that have been transduced with sgRNA libraries, but not by selecting clones with verified knockout efficiencies (Discussed by David Root in Genome Biol. 16: 260.). It is inevitable that the efficiency of knockout based on the CRISPR/Cas9 system is the key for the success of such screens and other experiments that depend on the phenotypic changes in heterogeneously edited cell population. Our results indicate that we do achieve efficient knockout of Ire1α ([Figure 6C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}), and observe clear phenotypic changes upon deletion of Ire1α ([Figure 6F, 6G](#fig6){ref-type="fig"}).

> 2\) Regarding the link between ER and IRE1, please see reviewer 1 point 3 and reviewer 3 point 3.

Two reviewers brought forth inquiry about the regulation of Ire1α activation on HSPCs. We started by investigating the changes that occur to the global chromatin landscape in hematopoietic precursor cells using ATACseq. Using bioinformatics analyses, we identified differentially regulated peaks in Oil- and E2-treated HSCs, and discovered that differential ATAC-seq peaks in E2-treated HSCs are enriched for estrogen response elements (ERE). One of the E2-specific ATAC peak was found upstream of Ern1 (which encodes for Ire1α) and contained a consensus ERE. To determine if this region was sufficient to activate Ire1α expression, we cloned the upstream regulatory region of Ire1α into a luciferase dual reporter assay and found that luciferase activity increased in an E2- and ERα-dependent manner. This activity depended on ERE since mutating the ERE ablated the transactivation property of this sequence. Finally, we performed ChIP-qPCR to test whether ERα occupies Ire1α upstream locus in HSPCs. We observed an increase in ERα binding at the ERE locus of Ire1α in E2-treated hematopoietic progenitor cells. These results indicate that Ire1α is a direct target of ERα in HSPCs. These data have been compiled into a new section of the manuscript, the results of which can be found in the newly added [Figure 5](#fig5){ref-type="fig"}.

> 3\) Regarding the effect on target genes, including Myc, please see reviewer 1 point 2 and reviewer 2 point 2.

We adopted our CRISPR strategy to address the potential relationship between Ire1 and Myc target activation. We cultured CRISPR-edited LSK cells in vitrowith or without exogenous E2 and checked mRNA expression of several Myc targets identified in the GSEA. We first confirmed that Ire1α is induced upon E2 treatment in vitro ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), similar to what we observed in vivo ([Figure 4D-E](#fig4){ref-type="fig"}). E2 induced the expression of several Myc target genes identified by GSEA ([Figure 4---figure supplement 1B-H](#fig4s1){ref-type="fig"}). Among these Myc target genes, some of them depended on Ire1α to become induced by E2 ([Figure 4---figure supplement 1B-D](#fig4s1){ref-type="fig"}), whereas other genes did not ([Figure 4---figure supplement 1E-H](#fig4s1){ref-type="fig"}). This indicates that some of these target genes are downstream of Ire1α, but the entire Myc target gene set does not behave in this manner. We also note that although GSEA detected global upregulation of Myc target genes, c-Myc, L-Myc, or N-Myc were not induced. Since Myc has a large impact on the expression of genes involved in cell growth and proliferation (Cell. 151:56-67), it is likely that many stimuli that promote proliferation will exhibit increased "Myc target" expression by GSEA even though those stimuli may not involve Myc.

An additional question was on the heterogeneity of HSCs, and whether E2 is acting upon a certain subset of HSCs. We addressed this question by using CD150 as a surrogate marker for myeloid-biased HSCs (PNAS. 107:5465,

Cell Stem Cell. 6:265). We sorted CD150^HI^, CD150^LO^, and CD150^NEG^ CD48^-^ LSKs from Oil- and E2-treated mice and measured Ire1α expression. Ire1α expression was increased upon E2-treatment equally in each population, suggesting that E2 is not specifically acting on myeloid-biased CD150^HI^ HSCs ([Figure 4---figure supplement 2A-B](#fig4s2){ref-type="fig"}).

These data address the main concerns brought forth by the reviewers.

> Moreover, there was agreement on the need to further clarify the cell autonomous/non-autonomous action of E2, including a deeper discussion of the consistency of results (see reviewer 1 point 1 and reviewer 3 point 1.

In addition to the aforementioned data, we revised the manuscript to address several other comments. Of note, there was discussion regarding the cell autonomous vs. cell non-autonomous action of E2 on HSPCs and an issue of clarifying the consistency of the results. We have revised the text to reflect our position that E2 is acting as a systemically acting extrinsic regulator of HSC function, and removed any claims implying that ERα acts solely on HSCs. Moreover, we performed additional experimental shown in [Figure 6G](#fig6){ref-type="fig"} and examined how E2 and Ire1α regulates HSPCs recovery in the bone marrow.

These additional experiments highlight the robustness of E2 as a positive regulator of hematopoietic regeneration. We believe that the new data and revisions have resulted in substantial improvement of the original manuscript.

> Addressing the other points raised would of course be beneficial; however there is a concern that addressing the two major concerns may require mouse models or time course experiments that might require a longer timeframe of revision than normally allowed by eLife and it is for this reason that we invite you to let us know what timeline you could propose.

Reviewer \#1:

> 1\) The authors investigate in detail the role and mechanism of action of estrogen stimulation on hematopoietic stem cells, and perform important transplantation experiments that were missed in previous studies. Linking the UPR to the E2 response is very novel and a finding that advances not only the HSC field.
>
> The overall work is very good and elegant, however my major concern is the repeated comment that ER works cell intrinsically only. It certainly works within HSCs, however without any experiments with chimeric mice in which either the hematopoietic system or the stroma lack ERα it is impossible to conclude that ER signaling does not play a role indirectly through the stroma/ HSC niche too. In fact, some in vitro experiments only partially reproduce the in vivo findings, and in most experiments HSCs harvested from treated mice are used, rather than HSCs treated ex vivo. The authors could either generate the chimeras, which is however time-consuming as a pre-experiment, or be more careful in their comments.

We agree that we cannot exclude the possibility that E2 affects the HSC niche to improve hematopoietic regeneration. This could potentially explain why we only see a partial rescue of hematopoietic cells after irradiation ([Figure 2E-G](#fig2){ref-type="fig"}). We have toned down our comments that the effect of E2 is solely dependent on ERα in hematopoietic cells (subsection "Estradiol promotes the regenerative capacity of HSCs", third and last paragraphs; subsection "Estradiol promotes hematopoietic recovery after irradiation", first paragraph; subsection "Estradiol accelerates hematopoietic progenitor cell regeneration after ionizing radiation", last paragraph). Additionally, we revised the Discussion to suggest that the HSC niche could also be a contributing factor to the increased hematopoietic regeneration (third paragraph).

> 2\) The other major missing point in terms of functional characterization of HSCs from E2-treated mice is a limiting dilution transplantation assay, so that not only groups of 100 HSCs, but also smaller doses, e.g. single or 5-10 HSCs can be assessed and frequencies can be estimated. This seems important especially in view of up-regulation of cMyc following E2 treatment, with Myc activation being consistently linked to loss of HSC function. Is it possible that E2 treatment leads to further proliferation of already active HSCs rather than dormant (e.g. label retaining) ones?

In terms of the effect of E2 on HSC proliferation, we have previously published the results of an H2B-GFP labeling experiment (Nature. 505:555-558). We demonstrated that E2 promotes proliferation of both H2BGFP(high) and H2B-GFP(low) HSCs contains dormant and active HSCs, respectively, suggesting that E2 is not selective on the subtypes of HSCs it acts on.

To further test whether E2 acts on a particular subpopulation of HSCs, we investigated Ire1α expression HSC subpopulations distinguished by the level of CD150 expression. It has been shown by Derrick Rossi's group that CD150-high HSCs are enriched for myeloid-biased HSCs, whereas HSCs with lower CD150 expression contain balanced and lymphoid-biased HSCs (PNAS. 107:5465). It is also known that CD150-high HSCs are enriched for those with lower side population (SP) phenotype, which are also more quiescent than the upper SP HSCs (Cell Stem Cell. 6:265). Ire1α expression did not differ between these populations, suggesting that E2 does not specifically act on myeloid-biased CD150-high HSCs. We have included these data in [Figure 4---figure supplement 2A, B](#fig4s2){ref-type="fig"}.

We also note that although GSEA detected global upregulation of Myc target genes, c-Myc, L-Myc, or N-Myc were not induced. Since Myc has a large impact on the expression of genes involved in cell growth and proliferation (Cell. 151:56-67), it is likely that many stimuli that promote proliferation will exhibit increased "Myc target" expression by GSEA even though those stimuli may not involve Myc. Additionally, it has been shown that adult HSCs are generally c-Myc-low, but fetal liver HSCs, which are more proliferative than adult HSCs and have extensive self-renewal capacity, have higher Myc expression than adult HSCs (Nature Immunology. 11:207). Interestingly, we found that the expression of Lin28 and Hmga2 are induced in E2-treated adult HSCs. These two genes are highly expressed in fetal liver HSCs compared to adult HSCs and regulate self-renewal (Nature Cell Biology. 15:916, J Exp Med. 213:1497). This raises a possibility that E2 induces a fetal-type self-renewal program in adult HSCs (potentially through Lin28 or Hmga2), paralleling the activation of the cell cycle and increased myeloid reconstitution potential. We hope to test this hypothesis in near future.

> 3\) Another major point regards the connection between ERα and the UPR. Is Ire1α a direct target of ERα? This could already be known, and therefore mentioned, or checked through bioinformatics analysis of the Ire1α promoter, and ideally a ChiP experiment.

For the full response, please see response to main concern point \#2 above. The revised manuscript includes a new section in which we demonstrate that ERα associates with an upstream locus of Ire1α, highlighting that Ire1α is a direct target of ERα. We used ATAC-Seq to identify differentially regulated regions of accessible chromatin in HSPCs after E2 treatment, and identified a differentially regulated region of the Ire1α upstream region that contained a consensus estrogen response element (ERE). Using a dual luciferase assay and ChIP-qPCR assay, we confirmed that this region possesses E2- and ERα-dependent transactivation property, and that ERα occupies this site upon E2 stimulation in HSPCs. These new data are provided in the new [Figure 5](#fig5){ref-type="fig"}.

> 4\) Finally, I don\'t see anywhere the gating strategy used to identify HSC and progenitor cell populations. It is very important that these are shown as different gates are used by different research groups and it is easy to be transparent about the gates used, as long as they are consistent throughout the work shown.

We have included the gating strategy for HSCs in [Figure 1---figure supplement 1A-C](#fig1s1){ref-type="fig"}.

> 5\) The survival experiment described in [Figure 2](#fig2){ref-type="fig"} does not really add much to the previous experiment, showing recovery from a lower dose of irradiation. I would either remove the experiment entirely to avoid any reference to letting mice die as an experimental end point, which is unethical, or explain how the mice were humanely monitored.

We included these experiments because it has been previously established that the main cause of mortality after radiation is due to hematopoietic failure. The survival analysis is a standard assay used in many of the papers we cited in the manuscript that describes factors regulating hematopoietic regeneration after irradiation injury (for example, Nature Medicine. 23, 91--99). We monitored morbidity in accordance to IACUC guidelines for humane endpoints for laboratory animals, and this will be highlighted in the revised text.

Reviewer \#2:

> In their manuscript \"ERα promotes hematopoietic regeneration through the IRE1α-mediated unfolded protein response\" Nakada et al. provide evidence that estrogen receptor (ER) signaling promotes HSC regeneration following irradiation at least in part due to activation of the Ire1a branch of the unfolded protein response (UPR). Altogether the hypothesis is interesting and the work is a nice extension of prior studies in this area.
>
> I have a few major comments relating to improving the quality of the study:
>
> 1\) The implication of the data (and prior work from the Morrison lab) is that ER signaling promotes HSC proliferation. As such it would be important to distinguish whether the mechanism by which ER signaling promotes recovery is due to protection from apoptosis (given Annexin V data), proliferation or both, as either mechanism can lead to faster recovery of BM cell numbers.

We agree that both protection from apoptosis and increased proliferation may contribute of the faster recovery of BM cells. Determining the relative contribution of these two processes on BM recovery is a challenge, since we will need to block apoptosis and proliferation of HSPCs separately and examine the consequences of blocking these processes on BM recovery after irradiation. A previous report demonstrated that overexpression of BCl^-^2 substantially blocked apoptosis of BM cells after irradiation, but the BM cell number nonetheless dropped to \~10% of the steady-state level (Blood. 91:2272). Blocking HSC proliferation is also difficult since multiple cyclin/CDKs act redundantly (reviewed in J Cell Biol. 195:709). We modified the text to conclude that E2 promotes HSC proliferation and block IR-induced apoptosis, both of which may contribute to the faster recovery of BM cells, and avoid potential over-interpretation regarding the relative importance of preventing apoptosis vs. promoting proliferation.

> 2\) Along these lines, is UPR directly responsible for increased Myc/E2F gene levels and cell proliferation or vice versa? This can be tested in regenerative conditions using the CRISPR system developed by the authors and would define the epistatic relationship between these important and functionally interleaved gene programs in hematopoietic regeneration.

For the full response to this comment, please main concern point \#3 above. We now provide new data in [Figure 4---figure supplement 1B-H](#fig4s1){ref-type="fig"} showing that some Myc target genes are dependent on Ire1α for the induction after E2 treatment, whereas some other targets do not depend on Ire1α. It is likely that the Myc targets identified in the GSEA are not collectively downstream of Ire1α, and that other Ire1α- or UPR-independent mechanisms are likely to be in play.

> 3\) Overall a key finding of the paper is the dependence on Ire1α based on CRISPR. To fully substantiate the Ire1α findings to the reader I recommend that the authors show the full timecourse of hematopoietic regeneration following IR such as shown in [Figure 2A](#fig2){ref-type="fig"}, and demonstrate by directly interrogating the BM whether similar kinetics of BM and LSK recovery are observed as in [Figure 3A-C](#fig3){ref-type="fig"}, at least looking in the donor compartment if not BM as a whole.

We thank the reviewer for this advice. We have performed the analysis of quantifying HSPCs in the bone marrow after transplanting Ire1αedited LSK cells with or without E2 treatment. Whereas E2 treatment increased the frequency of Rosa26-edited LSK cells and myeloid progenitor cells, E2 treatment failed to promote HSPC regeneration when Ire1α was deleted. These results reinforce the idea that E2 promotes hematopoietic regeneration in a manner dependent on Ire1α. These new data are shown in [Figure 6F-G](#fig6){ref-type="fig"}. We opted not to perform detailed time course experiment after Rosa26- or Ire1α-editing and transplantation, followed by oil- or E2-treatment, since not only does this experiment use large numbers of mice (please note, that the same recipient mouse cannot be bled on two consecutive time points particularly after irradiation since it increases the mortality rate, requiring multiple cohorts for bleeding at different time points. Also LSK cells are scant before day 14 after TBI) but also because analyzing HSPCs as suggested by this reviewer is a more direct way to examine hematopoietic regeneration. In fact, we observed a much more clear effect of E2 and Ire1α deletion when we analyzed HSPCs as suggested.

> 4\) [Figure 5F](#fig5){ref-type="fig"} shows sensitization of LSK to stressors; on the flipside does Ire1α KD also abrogate any increases in colony forming activity in LSK, or is the colony forming phenotype only specific to HSCs?

We performed a CFU assay with LSK cells isolated from oil- or E2-treated mice, similar to what we performed for HSCs ([Figure 1](#fig1){ref-type="fig"}). We did not see significant effects of E2 on the frequency or the types of colonies formed after E2 treatment when LSK cells were plated, suggesting that the effects of E2 in enhancing the ability of form immature myeloid colonies are specific to HSCs.

Also, as shown in our previous [Figure 5F](#fig5){ref-type="fig"} (now [Figure 6D](#fig6){ref-type="fig"}), left panel black bars, deletion of Ire1α in control LSK cells showed no difference in CFU potential. Thus, Ire1α appears to be more important for colony formation when cells are challenged with proteotoxic stress.

Reviewer \#3:

> This study is an extension of a previous study showing E2 increases HSC proliferation and frequency and erythropoiesis (Nakada et al., 2014), showed E2 increases broad myelopoiesis, and uncovered the mechanistic link between E2 and UPR, a protective mechanism for HSCs (van Galen et al., 2014). They showed that IRE1-XBP1 branch of the UPR is responsible for E2\'s effect on HSCs, as deleting IRE1 using CRISPR in LSK cells blunted E2\'s effect on HSCs.
>
> 1\) Non-autonomous UPR refers to the phenomenon that ER stress in one tissue induces UPR in a remote tissue. If the authors claim that what they found here represents an example of non-autonomous UPR, they would need to show that ER stress in ovaries leads to release of E2, which activates UPR in HSCs. However, it does not seem to be the case here.

We have revised the text (Introduction, fourth paragraph and Discussion, last paragraph) to illustrate our viewpoint, which is that E2 is a systemic factor that activates UPR in HSPCs, and removed any claims that implied non-autonomous UPR in HSCs.

> 2\) The observation that E2 increases myelopoiesis but not lymphopoiesis is interesting. Do myeloid primed HSCs have increased ER stress than lymphoid primed HSCs? The authors propose IRE1 as an underlying mechanism. However, in [Figure 5G](#fig5){ref-type="fig"}, it appears that the effects of E2 and IRE1α are uncoupled. E2 increased WBC but IRE1α deletion had no effect on WBC. E2 had no effect on RBC but IRE1α deletion reduced RBC.

Using CD150 as a proxy for myeloid- and lymphoid-biased HSCs, we fractionated CD48^-^ LSK cells and examined whether Ire1α is induced in a particular subpopulation of HSCs (for example, myeloid-biased CD150-high HSCs). We observed similar increases of Ire1α mRNA levels in HSCs regardless of the CD150 expression levels, suggesting that E2 is not acting upon a subset of the HSC pool. This new data is provided in [Figure 4---figure supplement 2A, B](#fig4s2){ref-type="fig"}. In regards to the second part of the comment, we included additional replicates to the data illustrated in [Figure 6E](#fig6){ref-type="fig"} (previously [Figure 5G](#fig5){ref-type="fig"}), which allowed for a more robust and convincing interpretation of the data. Importantly, our new results shown in [Figure 6F-G](#fig6){ref-type="fig"} demonstrates that E2 promotes the recovery of immature HSPCs in the bone marrow of recipient mice, and this recovery depends clearly upon Ire1α. We believe that assessing HSPCs is a more direct way to examine hematopoietic regeneration, since the number of blood cells in peripheral blood can be regulated by multiple homeostatic mechanisms.

> 3\) The authors performed RNA-seq and found that UPR genes are upregulated in E2-treated HSCs. Importantly, they showed that the UPR upregulation upon E2 is dependent on ERα. How does E2-ERα upregulate IRE1? Does IRE1 promoter have ERα binding site? Does ERα bind to IRE1 promoter?

For our full response to this comment, please see main concern point \#2 above. As discussed above, we have provided a large amount of new data showing that ERα associates with the upstream region of Ire1α in E2 treated HSPCs. These data are provided in the new [Figure 5](#fig5){ref-type="fig"}.

> 4\) In [Figure 5E](#fig5){ref-type="fig"}, what\'s the editing efficiency? Typically, a pool of CRISPR edited cells do not show knockdown, but need to be selected for single clones that have efficient knockdown. Since the novel aspect of this study is the connection of E2 with UPR and the knockout mouse models for all three branches of UPR are well established, it makes more sense to use the KO mice.

For our full response, please see main concern point \#1 above. A clonal analysis of Ire1α-editing efficiency was conducted on LSK cells. As seen in [Figure 6---figure supplement 1D, a](#fig6s1){ref-type="fig"} high proportion (\~75%) of LSKs are edited using our previously established protocol, consistent with the immunoblotting data provided in [Figure 6E](#fig6){ref-type="fig"}. We agree with the reviewer that selecting clones with efficient knockout is a robust strategy to study the effects of gene ablation. Multiple clones should be selected to avoid potential clone-specific phenotypes. This approach is technically difficult to perform with HSPCs, since these cells cannot be maintained for a long period of time, which is needed to select single clones by antibiotics resistance or fluorescent marker expression. Our approach takes advantage of the high efficiency of editing (\~75%) in the bulk population, enabling us to examine the phenotypic changes in the bulk population, which has been taken by other groups as well (see response to main concern \#1). It is true that there will be a small fraction of cells that were not gene ablated in our approach, which might explain the modest effects we observed in [Figure 5G](#fig5){ref-type="fig"} of the original manuscript. To address this issue, we have repeated the experiments and we observed statistically significant effects of Ire1α ablation in all three parameters we tested (WBC, RBC, PLT), as shown in the new [Figure 6G](#fig6){ref-type="fig"}. As mentioned in response to comment \#2, we have added new data showing that E2 promotes the recovery of immature HSPCs in the bone marrow of recipient mice, and this recovery depends clearly upon Ire1α.

> 5\) The effect of E2 on hematopoiesis is inconsistent throughout the manuscript. e.g. in [Figure 2D-F, E2](#fig2){ref-type="fig"} significantly increases platelets. However, in [Figure 5G, E2](#fig5){ref-type="fig"} has no effect on platelets. It is unclear how robust the effect of E2 is.

As mentioned above, we have included additional experimental replicates to the figures in question. These additional replicates clarify the effects observed on hematopoietic regeneration. Furthermore, we have analyzed HSPCs in the bone marrow of the recipient mice (reviewer 2, comment 3). These additional data provided in [Figure 6F-G](#fig6){ref-type="fig"} are in agreement with our findings based on blood cell counts ([Figure 6E](#fig6){ref-type="fig"}), and demonstrate that E2 enhances recovery of HSPCs in an Ire1α-dependent manner. We postulate that since production of mature cells (such as platelets) involves multiple intermediate cell stages during differentiation and that it is also affected by a variety of homeostatic mechanisms (such as thrombopoietin production by the liver and the kidney), the end output (CBC data) may not be as robust as directly examining HSPCs.

> 6\) [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} is missing.

We apologize for this oversight. We have included the missing figure supplements in the revised manuscript.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> 1\) Subsection "Estradiol promotes protective unfolded protein response in HSCs", third paragraph. Please state clearly that clonal analysis of electroporated LSK cells indicated that about 25% of the clones were deleted ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). Nevertheless, bulk-modified cell populations used for subsequent experiments showed that....

We added this description that reads "Clonal analysis of electroporated LSK cells indicated that about 25% of the clones had deletions between the two sgRNA target sites, while another 50% of the clones had small indels detected by TIDE analysis ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). The bulk-modified cells were then..."

> 2\) Subsection "Estradiol activates the unfolded protein response (UPR) pathway in HSCs", first paragraph. In line with the detailed explanation presented in the response letter, please modify the text to indicate that a number of Myc target genes were induced by E2, even though c-Myc, N-Myc and L-Myc were not. It would be helpful to include the comments provided in this section of the response letter within the Discussion section of the manuscript.

We added the following sentence: "Several Myc target genes were induced by E2 treatment in vitro ([Figure 4---figure supplement 1B-H](#fig4s1){ref-type="fig"}), although c-Myc, N-Myc, and L-Myc were not induced in HSCs by E2 as determined by RNA-seq (data not shown)."

Additionally, we added a new paragraph discussing the changes in Myc targets without induction of Myc themselves (Discussion, third paragraph).

> 3\) Please indicate at least in the Materials and methods that, based on [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, HSCs were sorted as CD48-/low (and for brevity named CD48-) according to Kiel et al., Oguro et al. etc. There is much confusion in the field about where to place CD48 gates, and the more clarity is used in the presentations, the better. Overall, the gating schemes should include the experimental treatments and not just the control as presented in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. This is particularly true for readers who are evaluating how the E2 and IR treatment conditions change distribution of markers such as CD48 and CD150.

We modified the methods (subsection "Flow-cytometry and HSC isolation") to indicate that HSCs are defined as CD150^+^CD48^−/low^Lineage^−^Sca-1^+^c-kit^+^ cells, citing Kiel et al. and Oguro et al. We also replaced "CD48- "to "CD48-/low" throughout the manuscript, including [Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}. We also added the gating schemes of the E2 treated mice in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. We also added gating schemes of LSK cells with or without irradiation, in [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"} (we did not use CD150 or CD48 in irradiation studies, as described already in subsection "Estradiol accelerates hematopoietic progenitor cell regeneration after ionizing radiation").

> 4\) Please include the comments about variable effects on platelets production presented in the response letter within the Discussion section.

We added this new discussion to the Discussion section.
